NWU2013 -02-01 
Version 3.9, April  19, 201 9 
 
 –1– COVER PAGE  
 
DCP Protocol #:  NWU2013 -02-01  
 
Local Protocol #:  NCI 2013 -02-01 
 
A Phase I Trial of Inhaled Iloprost for the Prevention of Lung Cancer in Former Smokers  
 
Consortium Name *:   Northwestern Cancer Prevention Consortium  
Name of Consortium Principal  Seema A. Khan, MD   
Investigator:     303 E. Superior, Suite 4 -111 
  Chicago, IL 60611  
  Tel: 312 -503- 4236   
  Fax: 312 -503-2555  
  skhan@nm .org  
 
Consortium Name *:   Northwestern Cancer Prevention Consortium  
Name of Consortium  Co-PI:  Lifang Hou, M.D.  
680 N Lake Shore Drive, Suite 1400  
Chicago, IL 60611  
Phone: (312) 503 -4798  
Fax: (312) 908 -9588  
l-hou@northwestern.edu  
 
Organization Name:    University of Colorado Denver   
Protocol Chair :   York E. Miller, M .D. 
     1055 Clermont St., DVAMC  
     Pulmonary/111A  
     Denver, CO 80220  
     303-393-2869  
     303-393-4639  
     york.miller@ucdenver.edu  
 
Organization:     University of Colorado Denv er  
Co-Chair :    Robert L. Keith, M.D.  
     1055 Clermont St.  
     Research, Box 151  
     Denver, CO 80220  
     303-393-2869  
     303-377-5686  
     Robert.keith@ucdenver.edu  
 
Organization:      University of Colorado Denver   
Investigator:     Daniel Merrick  MD 
     Pathology  
     1055 Clermont St.  
     Denver, CO 80220  
     303-399-8020 ext 2700  
     303-393-5036  
     daniel.merrick@ucdenver.edu  
 
*No participant accrual occurs at this site  
NWU2013 -02-01 
Version 3.9, April  19, 201 9 
 
 –2– Organization:     National Jewish Health  
Investigator:     Moumita Ghosh, PhD  
     1400 Jackson Street, K1011A  
     Denver, CO 80206  
     303-270-2467  
     303-398-1225  
     Ghoshm@njhealth.org  
 
Organization *:    Northwestern University  
Statistician:     Borko D. Jovanovic, Ph.D.  
     680 North Lake Shore Drive  
 Suite 1102  
 Chicago, IL 60611  
 Tel: 312 -503-2008  
 Fax: 312 -908-9588  
 E-mail: borko@northwestern.edu  
 
 
IND Sponsor:   NCI/Division of Cancer Prevention  
    
IND#    Exempt  
Agent(s)/Supplier : Inhalational Iloprost (Systematic (IUPAC) name: 5-{(E)-(1S,5S,6R,7R) -7-hydroxy -
6[(E) -(3S, 4RS) -3-hydroxy -4-methyl -1-octen -6-inyl] -bi-cyclo[3.3.0]octan -3-
ylidene}pentanoic acid) supplied by Bayer -Schering/Actelion Pharmaceuticals 
(USA) /Bayer/Actelion Pharmaceuticals  
NCI Contract #  HHSN2612201200035I  
 
Protocol Version Date:  April 19, 2019  
 
Protocol Revision or   
Amendment #   Version 3.9 
  
 
 
 
*No participant accrual occurs at this site  
 
NWU2013 -02-01 
Version 3.9, April  19, 201 9 
 
 –3– SCHEMA  
 
 
 
A Phase I Trial of Inhaled Iloprost for the Prevention of Lung Cancer in Former Smokers  
 
 
 
 
 
  
 
 
 
 
  
  
 
  
 
  
 
 
  
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*See section 3 for further details  High risk former smokers (abstinent from smoking 
tobacco > twelve  months)  
Cohort A: 5.0 µg Q.I.D. 
daily inhaled Iloprost 
(40) vs. placebo ( 1)* 
Treatment for two months  Qualifying sputum cytologic dysplasia OR history 
of endobronchial dysplasia  
Bronchoscopy for eligible subjects  
Enrollment  for eligible patients with either sputum cytologic atypia of mild dysplasia or 
greater , or a history of bronchial biopsy with mild or greater  dysplasia , to either Iloprost or 
placebo. Cohort A will be open -label (non -randomized after the first 7 participants, who 
were randomized), Cohort B  will be open -label (non -randomized after 4 participants, who 
were randomized) .  
Cohort B: 5.0 µg B.I.D. 
daily inhaled Iloprost ( 5-
8) vs. placebo ( 2) 
Repeat baseline assessments and 
bronchoscopy  to evaluate toxicity profile, 
dosing compliance, and potential iloprost 
effect on endobronchial histology, serum 
proteins, and biopsy gene expression.  
Final evaluable:  
Cohort A (active) = 40 
Cohort A (placebo) = 1  
Cohort B (active) = 5-8 
Cohort B (placebo) = 2 Estimated attrition (8 -10) 
NWU2013 -02-01 
Version 3.9, April  19, 201 9 
 
 –4– TABLE OF CONTENTS  
 
 
COVER PAGE  ................................ ................................ ................................ ................................ ..............  1 
SCHEMA  ................................ ................................ ................................ ................................ ......................  3 
1. OBJECTIVES  ................................ ................................ ................................ ................................ .. 6 
1.1 Primary Objectives  ................................ ................................ ................................ ................................ ..........  6 
1.2 Secondary Objectives  ................................ ................................ ................................ ................................ ...... 6 
2. BACKGROU ND ................................ ................................ ................................ .............................  6 
2.1 Study Disease  ................................ ................................ ................................ ................................ ..................  6 
2.2 Study Agent  ................................ ................................ ................................ ................................ ....................  8 
2.3 Rationale  ................................ ................................ ................................ ................................ .........................  9 
3. SUMMARY OF STUDY PLAN  ................................ ................................ ................................ ... 13 
4. PARTICIPANT SELECTION  ................................ ................................ ................................ ....... 13 
4.1 Inclusion Criteria  ................................ ................................ ................................ ................................ ..........  13 
4.2 Exclusion Criteria  ................................ ................................ ................................ ................................ .........  14 
4.3 Inclusion of Women and Minorities  ................................ ................................ ................................ .............  15 
4.4 Recruitment and Retention Plan  ................................ ................................ ................................ ....................  15 
5. AGENT ADMINISTRATION  ................................ ................................ ................................ ....... 15 
5.1 Dose Regimen and Dose Groups  ................................ ................................ ................................ ..................  15 
5.2 Iloprost  Administration  ................................ ................................ ................................ ................................ . 16 
5.3 Run-in Procedures  ................................ ................................ ................................ ................................ .........  16 
5.4 Contraindications  ................................ ................................ ................................ ................................ ..........  16 
5.5 Concomitant Medications  ................................ ................................ ................................ .............................  16 
5.6 Dose Modification ................................ ................................ ................................ ................................ .........  16 
5.7 Adherence/Compliance  ................................ ................................ ................................ ................................ . 17 
6. PHARMACEUTICAL INFORMATION  ................................ ................................ ......................  17 
6.1 Study Agent (IND Exempt ) ................................ ................................ ................................ ..........................  17 
6.2 Reported Adverse Events and P otential Risks  ................................ ................................ ..............................  17 
6.3  Availability  ................................ ................................ ................................ ................................ ...................  19 
6.4 Agent Distribution ................................ ................................ ................................ ................................ .........  19 
6.5  Agent Accountability  ................................ ................................ ................................ ................................ .... 20 
6.6 Packaging and Labeling  ................................ ................................ ................................ ................................  20 
6.7 Storage  ................................ ................................ ................................ ................................ ..........................  20 
6.8 Registration/Randomization  ................................ ................................ ................................ ..........................  20 
6.9 Blinding and Unblinding Methods  ................................ ................................ ................................ ................  20 
6.10 Agent Destruction/Disposal  ................................ ................................ ................................ ..........................  21 
7. CLINICAL EVALUATIONS AND PROCEDURES  ................................ ................................ ... 22 
7.1 Schedule of Events  ................................ ................................ ................................ ................................ ........  22 
7.2 Baseline Testing/Pre -study Evaluation  ................................ ................................ ................................ .........  23 
7.3 Evaluation During Study Intervention  ................................ ................................ ................................ ..........  24 
7.4 Evaluation at Com pletion of Study Intervention  ................................ ................................ ...........................  25 
7.5 Post-intervention Follow -up Period  ................................ ................................ ................................ ..............  26 
7.6 Methods for Clinical Procedures  ................................ ................................ ................................ ...................  26 
8.  CRITERIA FOR EVALUATION AND ENDPOINT DEFINITION  ................................ ...........  26 
8.1 Prima ry Endpoint  ................................ ................................ ................................ ................................ ..........  26 
8.2 Secondary Endpoints  ................................ ................................ ................................ ................................ ..... 26 
8.3 Off-Agent Criteria  ................................ ................................ ................................ ................................ .........  26 
8.4 Off-Study Criteria  ................................ ................................ ................................ ................................ .........  27 
8.5 Study Termination ................................ ................................ ................................ ................................ .........  27 
9. CORRELATIVE/SPECIAL STUDIES  ................................ ................................ .........................  27 
9.1 Rationale for Methodology Selection  ................................ ................................ ................................ ...........  27 
9.2 Comparable Methods  ................................ ................................ ................................ ................................ .... 28 
10. SPECIMEN MANAGEMENT  ................................ ................................ ................................ ...... 28 
10.1 Laboratories  ................................ ................................ ................................ ................................ ..................  28 
10.2 Collection and Handling Procedures  ................................ ................................ ................................ .............  29 
NWU2013 -02-01 
Version 3.9, April  19, 201 9 
 
 –5– 10.3 Research Samples for Genetic/ Genomic Analysis:  ................................ ................................ ......................  30 
10.4 Shipping Instructions  ................................ ................................ ................................ ................................ .... 31 
10.5 Tissue Banking  ................................ ................................ ................................ ................................ ..............  31 
11. REPORTING ADVERSE EVENTS  ................................ ................................ ..............................  31 
11.1 Adverse Events  ................................ ................................ ................................ ................................ .............  32 
11.2 Serious Adverse Events  ................................ ................................ ................................ ................................  33 
12. STUDY MONITORING  ................................ ................................ ................................ ................  34 
12.1 Consortia 2012 Data Management  ................................ ................................ ................................ ................  34 
12.2 Case Report Forms  ................................ ................................ ................................ ................................ ........  34 
12.3 Source Documents  ................................ ................................ ................................ ................................ ........  34 
12.4 Data and Safety Monitoring Plan  ................................ ................................ ................................ ..................  35 
12.5 Sponsor , FDA , or Biomarker Development Partner  Monitoring  ................................ ................................ .. 35 
12.6 Record Retention  ................................ ................................ ................................ ................................ ..........  35 
12.7 Cooperative Research and Development Agreement (CRADA)/Clinical Trials Agreement (CTA)/ Material Transfer 
Agreement (MTA)/ Master Research Agreements  ................................ ................................ ................................ .. 35 
13. STATISTICAL CONSIDERATIONS  ................................ ................................ ...........................  35 
13.1 Study Design/Description  ................................ ................................ ................................ .............................  35 
13.2 Randomization/Stratification  ................................ ................................ ................................ ........................  35 
13.3 Accrual and Feasibility  ................................ ................................ ................................ ................................ . 36 
13.4 Primary Objective, Endpoint(s), Analysis Plan  ................................ ................................ .............................  36 
13.5 Secondary Objectives, Endpoints, Analysis Plans  ................................ ................................ ........................  36 
13.6 Reporting  and Exclusions  ................................ ................................ ................................ .............................  37 
13.7 Evaluation of Toxicity  ................................ ................................ ................................ ................................ .. 37 
13.8 Evaluation of Response  ................................ ................................ ................................ ................................ . 37 
13.9 Interim Analysis  ................................ ................................ ................................ ................................ ............  37 
13.10  Ancillary Studies  ................................ ................................ ................................ ................................ ...........  37 
14. ETHICAL AND REGULATORY CONSIDERATIONS  ................................ .............................  38 
14.1 Form FDA 1572  ................................ ................................ ................................ ................................ ............  38 
14.2 Other Required Documents  ................................ ................................ ................................ ...........................  38 
14.3 Institutional Review Board  Approval  ................................ ................................ ................................ ...........  38 
14.4 Informed Consent  ................................ ................................ ................................ ................................ ..........  38 
14.5 Submission of Regulatory Documents  ................................ ................................ ................................ ..........  39 
14.6 Other  ................................ ................................ ................................ ................................ .............................  39 
15. FINANCING, EXPENSES, AND/OR INSURANCE  ................................ ................................ ... 39 
REFERENCES  ................................ ................................ ................................ ................................ ............  41 
CONSENT FORM  ................................ ................................ ................................ ................................ ...... 43 
APPENDIX A  ................................ ................................ ................................ ................................ .............  56 
APPENDIX B  ................................ ................................ ................................ ................................ .............  57 
APPENDIX C  ................................ ................................ ................................ ................................ .............  58 
APPENDIX D  ................................ ................................ ................................ ................................ .............  60 
APPENDIX E ................................ ................................ ................................ ................................ ..............  61 
APPENDIX F  ................................ ................................ ................................ ................................ ..............  67 
APPENDIX G  ................................ ................................ ................................ ................................ .............  68 
NWU2013 -02-01 
Version 3.9, April  19, 201 9 
 
 –6– 1. OBJECTIVES  
 
1.1 Primary Objectives   
 
The primary objective of this study is to evaluate the toxicity of inhalational iloprost  administered to patients 
daily for 2 months, given QID.  
 
1.2 Secondary Objectives   
 
The secondary objectives are to evaluate the : 
 Compliance with QID dosing regimen  
 Effect on endobronchial histology  
 Effect on  expectorated sputum cytology by both standard cytologic analysis and an automated three 
dimensional morphologic analysis.  Effect on serum proteins , including ADIPOQ, C9, ATP5B, 
CHST15, SHBG, HNR NPA2B1,  quantitated by  a highly multiplexed  aptamer based anal ysis measuring 
approximately 1500 proteins .  The associations with individual proteins and dysplasia on baseline 
bronchoscopy found in the Phase IIb oral iloprost trial will be tested in this study as a validation.  
 Effect on endobronchial brushin g and biop sy gene expression   of PPARγ , GSTmu, Ces1, FosL1, 
cytochrome p4502e1, stearoyl coA desaturase 1, TNF superfamily member 9, TGFβ , Jun and a 46 gene 
panel associated with dysplasia persistence, using Affymetrix arrays.   The 46 gene panel previously 
associate d with dysplasia persistence will be tested in this study as a validation.  Endobronchial 
brushing gene expression panels previously reported as associated with dysplasia will be tested in this 
study for validation.  
 Improvement in COPD as measured by ABG ( improved ventilation perfusion matching), pulmonary 
function testing, 6 minute walk distance, quality of life (St. George’s respiratory questionnaire, COPD 
assessment test [CAT])  
 Whether the in vitro  response of cultured airway epithelial progenitor cells to iloprost is a predictor of in 
vivo response in study subjects.  
 
2. BACKGROUND  
 
2.1 Study Disease  
 
Squamous Cell Carcinoma:   The increased risk of developing lung cancer in ex -smokers (even many years after 
smoking cessation) and the fact the majority of lung cancers in the U .S. arise in former smokers 1, underscores 
the need for n ovel 
chemopreventive strategies 
2.  Squamous cell carcinoma 
of the lung (SCC) is one of 
the four major subtypes of 
lung cancer and is the 
second most common form 
of Non-Small Cell Lung 
Cancer, or NSCLC , 
(adenocarcinoma being the 
most common 3) and is 
commonly associated with  
tobacco smoke exposure .  
SCC typically arises from 
the central airways 
(including the trachea and 
segmental bronchi), and 
Normal  
 
Squamous Metaplasia  
 
Mild Dysplasia  
 
Figure 1 : Histology of Bronchial Squamous Epithelium  
Carcinoma in situ  
 
Severe Dysplasia  
 
Moderate Dysplasia  
 
NWU2013 -02-01 
Version 3.9, April  19, 201 9 
 
 –7– histological studies have clear ly shown a series of predictable pathologic changes preceding invasive 
bronchogenic carcinoma 4,5.    
 
Typical human bronchi al epithelial changes induced by tobacco smoke are shown in Figure 1 .  
Autofluorescence bronchoscopy (AFB) can be utilized to reproducibly detect these lesions .  When compared to 
routine white light bronchoscopy, AFB  more reliably detects pre -malignant lesions in the central airways. Many 
patients in the trials confirming the superiority of AFB  were recruited to trials conducted at the University of 
Colorado Denver and the Denver VA Medical Center 6.  Our subsequent trials have proven that AFB is the 
preferred modal ity for detecting angiogenic squamous dysplasia (ASD) 7, a central airway lesion characterized 
by capillary blood vessels projecting into metaplastic or dysplastic squamous bronchial epithelium.   
 
Eicosanoids are a family of bioactive lipids produced from arachi donic acid (AA) liberated by  the action of 
cytosolic phospholipases A2 ( cPLA 2). AA is metabolized through three major pathways, cyclo -oxygenase 
(COX), lipoxygenase (LO) and cytochrome P450, to produce a family of bioactive lipids which have both pro - 
and a nti-tumorigenic activities in lung cancer .  Metabolic products downstream of COX include prostaglandins, 
prostacyclins and thromboxanes.  Prostaglandins have been most extensively  studied in  relation to 
carcinogenesis . In NSCLC, increased production of prostaglandin E 2 has been shown to promote carcinogenesis, 
progression and metastasis, through effects directly on the cells that become cancer cells, as well as upon the 
tumor microenvironment.  Inhibition of COX activity decreases prostaglandin productio n and prevents lung 
cancer in some , but not all , animal models 8,9.  However, non -specific COX inhibition (most notably with 
aspirin) has not been proven to reproducibly prevent lung cancer in large human trials  with cancer incidence as 
the endpoint  10.   
 
In 2011, a meta -analysis of all randomized trials of daily aspirin versus no aspirin has been published.  Eight 
eligible trials, comprised of 25,570 patients and 674 cancer deaths, were analyzed and demonstrated that those 
on aspirin had reduced deaths due  to cancer (OR = 0.79; 95% CI 0.68 -0.92, p = 0.003).  In the seven trials in 
which individual patient data was available, the protective effect of aspirin for all cancers (HR = 0.62; 95% CI 
0.47-0.82, p = 0.001) was only apparent after 5 years follow -up.  In this analysis of 5 years or greater follow -up, 
there was a trend towards protection from lung cancer (HR = 0.68; 95% CI 0.42 -1.10, p = 0.11).  In three trials, 
longer follow -up, out to 20 years, was available.  In these trials, there were 1634 cancer de aths in 12,659 
participants and the analysis  demonstrated significant reduction in lung cancer death (HR = 0.68, p < 0.01) with 
0-10 years follow -up.  The curves for lung cancer death with and without aspirin begin to separate at 4 years 
follow -up and the protective effect increases to yield a HR = 0.71 (p < 0.002) with 20 years follow -up11 . The 
effect on lung cancer death risk is confined to adenocarcinoma and is not found in small cell or squamous cell 
lung cancer.   This analysis suggests that for chemop revention trials to demonstrate efficacy, 5 years of treatment 
and long follow up periods may well be required.    
 
Lung targeted prostacyclin synthase overexpression increases lung prostacyclin levels and protects mice from 
multiple chemical, including tob acco smoke, lung carcinogenesis models12,13.  The prostacyclin analog, iloprost, 
is also effective in murine lung chemoprevention 14.  Furthermore, oral iloprost , a stable prostacyclin analog,  
administration improves bronchial epithelial  premalignant  dyspl asia in former, but not current smokers15.  
Therefore, additional investigation of the potential of iloprost for lung cancer chemoprevention is needed.   The 
University of Colorado Cancer Center investigators have extensive experience in identifying current  and former 
smokers at high risk for the development of lung cancer16.  For the previous oral iloprost and the ongoing 
pioglitazone chemoprevention trials, former smokers have been recruited from the Denver Veterans Affairs 
Medical Center and University of  Colorado Hospital Pulmonary clinics, using inclusion criteria of either mild or 
greater sputum atypia or a history of endobronchial dysplasia on a previous bronchoscopy with 58% and 57% 
respectively having endobronchial dysplasia on the subsequent study b ronchoscopies15.  Analysis of recruitment 
data from the ongoing pioglitazone trial demonstrates that approximately 63% of former smokers in our 
recruitment population have at least mild sputum atypia and 23% of former smokers in our recruitment 
population go on trial.  
 
NWU2013 -02-01 
Version 3.9, April  19, 201 9 
 
 –8– 2.2 Study Agent  
 
Iloprost : This will not be the first trial administering inhaled iloprost , a stable prostacyclin analog, to humans. It 
is an FDA approved drug for the acute and chronic treatment of pulmonary hypertension (PH) , and has clinically 
been used in subjects for many years . However, inhaled iloprost dosing for PH is 6 -9 times per day, a regimen 
that would not be acceptable for a chemopreventive indication.  We therefore propose to study the drug at a 4x 
per day (QID)  dosing regimen , and believe that this  is an acceptable scheduling  for a chemopreventive 
intervention .  The initial do se for the subject will be 2.5 µ g per inhalation  and they will be directly observed in 
clinic for side effec ts.  They will then begin on the 5 µg dose. If this is not tolerated, t he dose level will de -
escalate to 2.5 µg.  There is preclinical data to suggest that cyclical dosing may be more efficacious for 
preventing cancer17,18 and our clinical endpoint is diffe rent than those in pulmonary hypertension studies  where 
continuous vasodilatation of the pulmonary vasculature is the goal .  As previously described, increasing 
prostacyclin levels in the lung by targeted overexpression of prostacyclin synthase has been de monstrated to 
have a strong chemopreventive effect in multiple murine chemical carcinogenesis models, including a tobacco 
smoke exposure model12,13.  This effect has been demonstrated to be mediated by PPARγ , not the cell surface 
prostacyclin receptor14.  A Phase II trial in humans with endobronchial dysplasia as the primary endpoint was 
carried out in high risk current and former smokers15.  In this trial, no improvement in endobronchial dysplasia 
was seen in current smokers, but significant improvements w ere seen in former smokers.  Therefore, we 
hypothesize that the effect of continued smoking overcomes any chemopreventive actions of iloprost . 
 
Because Iloprost is a n FDA approved agent, and has been evaluated in several phase III trials, there is an 
advan ced understanding of the toxicities associated with its use. In general, Iloprost is well tolerated, even at the 
more frequent dosing schedules of 6 -9 times per day used for the treatment of primary pulmonary hypertension.  
Listed in Table 1  are common tox icities associated with the use of inhaled Iloprost , as summarized in the FDA 
package insert .   Additional data from a placebo controlled randomized controlled trial in which inhaled iloprost 
dose was  μg 6 -9 times daily demonstrates similar toxicities, in cluding increased cough (27% iloprost, 18% 
placebo), flushing (27% iloprost, 12% placebo) headache (13% iloprost, 9% placebo)  and syncope (8% iloprost, 
5% placebo)19. These will be measured by and captured on case report forms based on standard Common 
Term inology Criteria for Adverse Events (CTC AE) version 4.0 (National Cancer Institute 2009) .   
 
 

NWU2013 -02-01 
Version 3.9, April  19, 201 9 
 
 –9– 2.3 Rationale  
 
Background:  
Extensive work conducted by our group has shown that prostaglandin I 2 (PGI 2, prostacyclin) inhibits lung 
carcinogenesis in pre -clinical models12. Transgenic mice  with selective pulmonary PGI 2 synthase (PGIS) 
overexpression exhibited significantly reduced lung tumor multiplicity and incidence in response to either 
chemical carcinogens or exposure to tobacco smoke 12,13, suggesting  that manipulation of the arachidonic acid 
pathway downstream from COX is an attractive target for lung cancer prevention.  Our group has also shown 
that i loprost , a long -lasting prostacyclin analog ue that is currently FDA approved for the treatment of pulmonary 
hypertension , inhib its lung tumorigenesis in mice, both in a chemopreventive and chemotherapeutic setting 14.  
Studies using mice deficient in the cell surface prostacyclin receptor (IP) have demonstrated that 
chemoprevention is not dependent on IP expression  14.  Addi tionally, prostacyclin analogues, like i loprost , 
activate  the peroxisome proliferator activated receptor ( PPAR γ) response element14.  PPAR γ over expressing 
mice have similar resistance to chemical carcinogenesis as do prostacyclin over expressing mice, sup porting the 
concept that part of the chemopreventive activity of prostacyclin analogs is mediated by PPAR γ 12-14.  These 
studies led  to the implementation of a double -blind, placebo controlled clinical chemoprevention trial in which 
patients at high risk for lung cancer  (as defined by tobacco exposure, sputum cytologic atypia, and 
endobronchial dysplasia)  were treated with oral ilopros t for 6 months.  This trial demonstrated significant 
improvement of endobronchial dysplasia , but this was evidently only  in former  smokers 15. This is t he first 
chemoprevention trial to show improvement of its primary endpoint, endobronchial histology.  Importantly, t he 
iloprost trial utilized oral iloprost, a compound that is no longer produc ed due to a complicated manufacturing 
process and lack of additional patent life.  However, an inhaled version (delivered by a special nebulizer  
manufactured by Accredo ) has been developed and is currently FDA approved for the treatment of pulmonary 
hypert ension.  Importantly , delivery via inhalation offers the highly desirable advantage of selective delivery to 
the target organ, thereby minimizing systemic delivery and associated systemic toxicity.  When used for the 
treatment of pulmonary hypertension, Ilop rost is given 6 -9 times per day. This high frequency dosing schedule 
is not optimal for a chemoprevention strategy , as compliance would not be expected to be high .  However, 
cyclical treatment with another prostacyclin analog, cicaprost, has been demonstra ted to be effective in 
suppressing metastasi s17,18. Therefore, we propose to study inhaled iloprost in a phase I study with a lower 
dosing frequency and novel endpoints and biomarkers that are relevant to lung cancer chemoprevention. The 
proposed project w ill allow us to investigate a new and novel delivery method for a medication proven to have 
positive effects in a prior phase II study.  
 
Hypothesis for primary and secondary objectives:   
Overall Hypothesis:  Inhalational iloprost will be well tolerated and  will activate pathways in the 
pulmonary epithelium  relevant to lung carcinogenesis and chemoprevention efficacy .  
 
Target population:  
We propose to enroll  only high risk former smokers , as our original oral iloprost trial did not demonstrate 
improvement i n current smokers .  Entry criteria are based on our positive oral iloprost study14 and will consist 
of: age > 18; history of tobacco exposure with > /= 20 pack years; former smoker (no smoking in the prior 12 
months); at least mild sputum cytologic atypia and/or prior history of endobronchial dysplasia.  Subjects from 
prior chemoprevention trials will need to be off investigational agents for at least  12 months.  
 
Agent:   
Inhalational Iloprost (Systematic (IU PAC) name: 5-{(E)-(1S,5S,6R,7R) -7-hydroxy -6[(E) -(3S, 4RS) -3-
hydroxy -4-methyl -1-octen -6-inyl] -bi-cyclo[3.3.0]octan -3-ylidene}pentanoic acid)  supplied by Bayer -
Schering/Actelion Pharmaceuticals (USA)  
 
NWU2013 -02-01 
Version 3.9, April  19, 201 9 
 
 –10– Endpoints:   
 
Primary Objective:  
The primary objective of this study is to evaluate the toxicity of inhalational iloprost  administered to  patients 
daily for 2 months, given QID.  
 
Secondary Objectives:  
 
The secondary objectives are to evaluate the  
 • Compliance with QID dosing regimens  
 • Effect on endobronchial histology  
 Effect on  expectorated sputum cytology by both standard cytologic analysis and an automated          
 three dimensional morphologic analysis.  
 • Effect on serum proteins , including ADIPOQ, C9, ATP5B, CHST15, SHBG, HNRNPA2B1,  
quantitated by  a highly multiplexed  aptamer based analysis  measuring approximately 1500 
proteins . 
 • Effect on endobronchial brushin g and biopsy  gene expression  of PPARγ, GSTmu, Ces1, FosL1, 
cytochrome p4502e1, stearoyl coA desaturase 1, TNF superfamily member 9, TGFβ, Jun and a 
46 gene panel associated with dysplasia persistence.  
• Improvement in COPD as measured by ABG (improved ventilation perfusion matching), 
pulmonary function testing, 6 minute walk distance, quality of life (St. George’s respiratory 
questionnaire, COPD assessment test [CAT]) . 
• Whether the in vitro  response of cultured airway epithelial progenitor cells to iloprost is a 
predictor of in vivo  response in study subjects .  . 
 
 
Choice of techniques for endpoint  evaluation:  
 
Toxicity:   Toxicity will be  assessed at study visits using the NCI criteria and recorded in case report forms.  
 
Compliance:  Compliance will be measured by interrogation of the I -neb AAD device.  The manufacturer, 
Accredo , has developed softwa re that interfaces with the AAD device and provides dosing information.  In 
addition, patients are requested to complete a drug diary which is reviewed at each study visit.  
Effect on endobronchial histology:   Biopsies will be formalin fixed, paraffin embedded, cut into 4 μM 
sections, mounted on glass slides and stained with hematoxylin and eosin.  Bronchial histology will be graded 
from using the World Health Organization criteria and assigned a score accordi ng to the following system: 1, 
normal; 2, reserve cell hyperplasia; 3, squamous metaplasia; 4, mild dysplasia; 5 moderate dysplasia; 6, severe 
dysplasia; 7, carcinoma in situ; 8, invasive carcinoma4.  All biopsies will be graded by Dr. Daniel Merrick, the 
study pathologist, in a blinded fashion.  
Automated Three Dimensional Morphologic Analysis of Sputum Cells:  Sputum cytology is currently the 
only way to non -invasively measure bronchial epithelial dysplasia.  However, conventional sputum cytology has 
not be en formally evaluated as a marker of endobronchial dysplasia.  VisionGate, Inc., has developed an 
automated system for the three dimensional analysis of epithelial cells in sputum  (The LuCED ® test.  This 
automated system has shown promising preliminary res ults in the diagnosis of lung cancer from sputum20.  The 
analytic software can potentially detect dysplasia , however this is a research focus in the development of the 
technology .  Sputum is collected at the beginning and end of the trial and conventional cytology scored by the 
study pathologist.  We will also process sputum from the same timepoints for the automated three dimensional 
morphologic analysis.  The results of automated analysis will be compared to the scoring by the study 
pathologist.  In addit ion, changes in the cytologic grade as determined by the automated system will be 
compared to changes in endobronchial histology.  The NCI has agreed to supply VisionGate with sputum 
aliquots  and de -identified clinical information  for this purpose. If the three dimensional morphologic analysis of 
NWU2013 -02-01 
Version 3.9, April  19, 201 9 
 
 –11– sputum cells accurately mirrors endobronchial histology, this could lead to elimination of the need for 
bronchoscopy in future chemoprevention trials.  
 
Serum protein quantification by aptamer based analysis: Explor atory analysis of serum or plasma from the 
oral iloprost chemoprevention trial has identified several proteins which are correlated with dysplasia on 
baseline bronchoscopy; determining which, if any, of these are validated in an independent test set will b e a 
primary goal of this exercise.  In addition, we will perform exploratory analyses for serum proteins correlated 
with iloprost administration and histologic response .  
 
Biospecimens, including bronchial biopsies, urine and blood, were banked at enrollme nt and completion on each 
subject in the Phase II iloprost trial.  The expression of endobronchial miRNAs has been published and an 
analysis of eicosanoid levels in urine has been completed21.  Recently, serum taken at enrollment and trial 
completion has b een analyzed on the 125 subjects who completed this trial using the highly multiplexed aptamer 
based assay for serum proteins developed by SomaLogic, Inc.  The assay detects > 1, 500 proteins in a 50 μl 
serum sample with a mean detection limit of 40 fM22.  Our study design is to run the protein analysis on 
enrollment and completion sera from all subjects in one batch; this has been completed.  For data analysis, we 
have chosen to initially break the baseline analysis into a training set (2/3) and a blinded t est set (1/3) for 
correlation of protein abundance with baseline parameters including age, sex, pulmonary function and dysplasia 
grade.  After this is completed, data analysis will proceed on completion samples as well in a similar test 
set/training set des ign with the goal of discovering biomarkers 
that predict response to iloprost.  At present, only the baseline 
training set has been analyzed.  While these results are highly 
preliminary and are to be considered confidential, there are some 
highly tantalizi ng findings.  Six proteins tracked with maximum 
dysplasia grade on the baseline bronchoscopy.  The uncorrected 
p values are shown in Table 2. When adjusted for false 
discovery, q values for most are approximately 0.3 (likelihood of 
having been discovered b y chance 30%).  The exception to this is 
SHBG, for which the q value = 0.05.   
 
 
Protein functions are shown in Table 3.  Of interest, C9 has been found to correlate with the presence of lung 
cancer and is a member of the SomaLogic classifier for diagnosing lung cancer.  HNR NPA2B1 has a long 
history as a potential lung cancer diagnosti c biomarker and has recently been demonstrated to regulate EMT in 
lung cancer cell lines23,24,25.  Adiponectin is an adipocyte derived protein that has been shown to  be negatively 
correlated with cardiovascular disease, diabetes and multiple forms of cancer.  Adiponectin null mice exhibit  
accelerated tumor growth26.  Adiponectin has been widely described as upregulated by PPAR gamma ligands27, 
like iloprost .  We are ea ger to determine if low adiponectin levels, associated with baseline higher dysplasia, are 
upregulated by iloprost and track with improvement in dysplasia.   
     
Protein  Function  
ATP5B  Mitochondrial ATP synthase  
CHST15  Chondroition sulfate sulfotransferase  
SHBG  Sex hormone binding globulin; promotes clearance of steroid hormones  
C9 Complement C9  
ADIPOQ  Adiponectin; inhibits cancer growth  
HNRNPA2B1  Ribonucleoprotein; promotes EMT  
    Table 3.   Proteins and function.  
 
Endobronchial brushing gene expression:  Recent chemoprevention trial s have  included complementary gene 
expression analysis of endobronchial brushings taken from the right mainstem bronchus28.  These studies built 
on previous studies of similar analyses of gene expressio n which discriminated smokers and non -smokers, as 
well as patients with and without lung cancer29.  The underlying hypothesis for this approach is that a field effect  
Table 2.  p values and fold changes (dysplasia 
grades 1+2 vs. 5+6) for proteins with possible 
correlation with baseline maximum dysplasia.  
 
Protein KS Distance* p.value Fold Change**
ATP5B 0.56 0.0009 1.35
CHST15 -0.52 0.0024 0.82
C9 0.52 0.0027 1.14
SHBG -0.50 0.0036 0.52
ADIPOQ -0.50 0.0036 0.71
HNRNPA2B1 0.39 0.0420 1.60
*Negative values are lower as Max Path increases
**Relative to Max Path 1&2
NWU2013 -02-01 
Version 3.9, April  19, 201 9 
 
 –12– exists in the airway epithelium reflecting exposure and disease.  We propose exploratory analysis of 
endobronchial gene expression as a measure of exposure to inhaled iloprost.  We have previously published 
statistically significant alterations in gene expression in the alveolar type II cells isolated from prostacyclin 
synthase overexpressor m ice (Table 4) and these provide multiple candidates which we anticipate may also 
exhibit similar changes in human airway epithelium upon iloprost exposure13.   
 
Endobronchial biopsy gene expression:   We propose to analyze gene expression alterations induce d by 
inhaled iloprost in dysplastic lesions sampled by biopsy as well as in the general airway field as sampled by 
brushing.  Dr. Daniel Merrick , a pathologist at University of Colorado Denver,  and colleagues have developed a 
46 gene classifier for discrim inating persistent dysplasias from those which spontaneously regress  (Figure 2 ).  
We will carry out exploratory analyses to determine if gene expression changes occur with iloprost exposure  
that may potentially be informative of specific mechanisms by whi ch iloprost mediates improvement in 
dysplasia.  
 
 
Chronic obstructive lung disease endpoints:   Pulmonary function testing and 6 minute walk data will be 
measured by pulmonary function staff at Denver VAMC.  The St. Georges Respiratory Questionnaire and 
COPD Assessment Test will be administered by clinical trial coordinators.  
 
Airway epithelial pro genitor cell culture and response to iloprost :  Bronchial biopsies will be taken from an 
area suspicious for dysplasia and an area that appears normal.  These will be cultured as described and 
transferred to an air liquid interface culture in which dysplas ia is recapitulated (Ghosh et al, in preparation).  
Cultures will be treated with either vehicle or iloprost and assessed for both self renewal and differentiation to 
ciliated and secretory cells.  
Regressive N=15 Persistent N=23 Figure 2.  Heat Map of 46 Gene “Classifier” for 
Prognostic “Persistent” versus “Regressive” Dysplasia.  
Affymetrix Gene 1.0ST array data from N=23 persistent 
(moderate or worse) dysplasia compared to N=15 
regressive (spontaneous) dysplasia samples.  46 gene 
classifier developed from genes with FDR = 0.02 (P 
values, 10-4.  Permutation Test P value for leave on e out 
cross -validation demonstrated p<0.0004.  
 
Table 4: Gene Expression  
Overexpressed   
Fold 
Change    
Underexpressed   
Fold 
Change  
PPAR γ 1.8  Cytochrome 
p450, 2e1  10.4 
Glutathione S -transferase, mu1  1.4  Stearoyl -
coenzyme A 
desaturase 1  2.6 
Carboxylesterase 1 (Ces1)  2.7  TNF superfamily 
member 9  2.5 
Prostacyclin Synthase (PGIS)  12.9  TGF -β 2.1 
Fos-Like antigen (FosL1)  1.6  Jun oncogene  1.4 

NWU2013 -02-01 
Version 3.9, April  19, 201 9 
 
 –13–  
3. SUMMARY OF STUDY PLAN  
 
1. Subjects at high risk for the development of lung cancer as defined by a 20 pack -year or greater 
smoking history and the presence of mild or greater sputum atypia or mild or greater endobronchial 
dysplasia on a previous bronchoscopy  will be recruited for t he study from the Denver Veterans Affairs 
Medical Center clinics .  Subjects seen at University of Colorado Hospital and National Jewish Health 
clinics may also be referred to the study , but will be enrolled as a non -veteran at the Denver Veteran’s 
Affairs Medical Center if eligibility is met . 
2. This was an open label dose de -escalation  trial. We initially  propose d to study two separate iloprost 
dosing regimens ( QID and BID ) with 20 enrolled  subjects in each  iloprost  dosing regimen  group  
(estimated attritio n of 20% during the study would result in 16 evaluable participants per group) . In 
Cohort  A, the first 7 subjects were randomized to iloprost versus placebo, with one participant receiving 
placebo, but the remaining 14 subjects will not be randomized and instead will be given active iloprost. 
This is due to lack of availability of the placebo. Within the BID group (Cohort B) , we randomized  4 
participants, until revision for protocol v3. 8 was been approved , due to the expiration of placebo in 
December 2018. After approval of protocol v3. 8, we register ed all proceeding participants to cohort B 
as open label (withou t randomization). Thus, 7 participants were  enrolled to cohort B: 5 active treatment 
BID, and 2 placebo . During the approval of protocol v3.9, we expect that up to 3 more patients will be 
enrolled into Cohort B open label. Thus, we expect Cohort B will have 5 -8 patients on active agent, a nd 
2 patients on placebo.  
3. An interim analysis was conducted after completion of Cohort A and discussed on March 26, 2019.  As 
toxicity was minimal with the QID regimen and compliance was good (65% achieved 80% c ompliance 
or more), a decision was made  to discontinue Cohort B and enlarge Cohort A to a maximum of 40 
participants  on active agent , in order to better assess any effe cts of inhaled iloprost on secondary 
biomark ers. We expect up to 147 people will participate in the “pre -screening” portion of this study.     
4. Subjects will be required to complete a physical exam, labs, smoking history assessment, bronchoscopy, 
sputum, EKG, PFT, exhaled carbon monoxide testing, 6 -minute walk test, and ques tionnaires  at the 
initial visit .  During treatment, subjects will complete physical exams, labs, carbon monoxide readings, 
toxicity assessments, and drug compliance  at the scheduled 30  and 60 day visits .  At the end of 
treatment, subjects will repeat earli er screening assessments to determine the outcomes of the primary 
and secondary objectives.  If our trial plans to enroll up to  50 subjects (2 treatment arms with 21 
subjects on arm A and 20-29 subjects on arm B ), we anticipate this taking about 36 months to complete  
enrollment . 
5. Subjects will be seen at 30 and 60 day visits and monitored for toxicity at those times.  A telephone call 
will be placed at 15 days after initiating treatment and subjects will be interviewed for toxicity, 
compliance and any proble ms with the protocol .  A 90 day visit is also made to evaluate for resolution 
of any symptoms which occur while on trial  or development of new symptoms after study drug 
withdrawal .  
 
Participants will be accrued and monitored for toxicity. Toxicity will be graded according to the NCI CTCAE 
version 4.0. If grade 2 , 3 or 4 toxicity thought to be at least possibly due to drug is experienced by a subject, 
then modifications based on specific dose schedules will be made as listed in Section 5.6.  
 
4. PARTICIPANT SELEC TION  
 
4.1 Inclusion Criteria  
 
4.1.1  Participants must have e ither sputum cytologic atypia of mild dysplasia or greater or a history of 
bronchial biopsy with mild or greater  dysplasia  within the past 12 months . 
 
4.1.2  Participants must have a s moking history of 20 pack -years or greater.  
NWU2013 -02-01 
Version 3.9, April  19, 201 9 
 
 –14–  
4.1.3 Participants must have the a bility to safely undergo bronchoscopy in the judgment  of the investigators.  
 
4.1.4 Participants must be age 18 - 85 years.   Because no dosing or adverse event data are currently available 
on the use of Iloprost  in participants  <18 years of age, children are excluded from this study but will be eligible 
for future pediatric trials, if applicable.  
 
4.1.5 Partic ipants must have ECOG performance status ≤ 1. Note: See  Appendix A  for ECOG Performance 
Status Table . 
 
4.1.6 Participants must have normal organ and marrow function as defined below:  
Leukocytes    ≥3,000/microliter  
Platelets    ≥100,000/microliter  
Total bilirubin    <2.0 mg/dl  
AST (SGOT)/ALT (SGPT)  ≤2.5 × institutional ULN  
Creatinine    <2.0 mg/dl  
 
4.1.7 The effects of Iloprost  on the developing human fetus at the recommended therapeutic dose are 
unknown. For this reason and because  prostacyclins  are known to be teratogenic, women of child -bearing 
potential  and men having intercourse with a woman of childbearing potential must agree to use adequate 
contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the  duration 
of study participation.  Should a woman become pregnant or suspect she is pregnant while participating in this 
study, she should inform her study physician immediately.  Note: Women are considered to be of child -bearing 
potential if they are not surgically sterile or are under the age of 65 and have menstruated within the last two 
years.  
 
4.1.8  Participants must be able  to understand and willing  to sign a written informed consent document.  
 
4.2 Exclusion Criteria  
 
4.2.1  Participants must not have  used any tobacco product in the past year . 
 
4.2.2 Participants must not be currently receiving or have previously received thiazolidinedione  treatment 
unless sputum atypia or endobronchial dysplasia are documented again after thiazolidinedione treatment a nd 
within 12 months of entry.   
 
4.2.3  Participants must not have been treated with iloprost  at any time .  Note: participants on the placebo arm 
of previous iloprost trials are eligible, but participants on the placebo arm of cohort A of this study may not  be 
enrolled in cohort B.  
 
4.2.4 Participants must not have used any other investigation agent within the last six months . 
  
4.2.5 Participants must not have a h istory of allergic reactions attributed to compounds of similar chemical or 
biologic compositio n of Iloprost . 
 
4.2.6 Participants must not have u ncontrolled intercurrent illness including, but not limited to, ongoing or 
active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia,  or 
psychiatric illness/social  situations that  in the opinion of investigators would jeopardize patient safety of data 
integrity. Note: Individuals who are HIV positive will not necessarily be excluded, will be considered on a case -
by-case basis, but will be required to meet criteria r elated to patient safety and data integrity, as assessed by 
investigators.   
 
NWU2013 -02-01 
Version 3.9, April  19, 201 9 
 
 –15– 4.2.7 Participants must not have a current or prior invasive malignancy within the past 6 months.   Participants 
may enroll prior to biopsy result report, unless there are findings at bronchoscopy suggesting an invasive 
malignancy.   History of the following curatively treated cancers during any time prior to screening is allowed: 
non-melanoma skin canc er, cervical carcinoma in situ, and bladder carcinoma in situ.  
 
4.2.8  Participants must not have received either chemotherapy or radiotherapy within the previous 6 months.  
Note: Participants receiving long -term adjuvant hormonal therapy (such as tamoxifen  or aromatase inhibitors 
for breast cancer) are allowed . 
 
4.2.9 Women must not be pregnant or breastfeeding.  I loprost is a prostacyclin  agent with the potential for 
teratogenic or abortifacient effects. Because there is an unknown but potential risk for a dverse events in nursing 
infants secondary to treatment of the mother with  iloprost, b reastfeeding should be discontinued if the mother is 
treated with  iloprost.    
 
4.2.10 As iloprost inhibits platelet function, patients must not be taking anticoagulants , with the exception of 
aspirin or other non-steroidal  anti-inflammatory medications.  
 
4.2.11 Due to risk for hypotension in patients on vasodilators or antihypertensive medications, participants 
must not have blood pressure <95 mm Hg systolic.   
 
4.3 Inclus ion of Women and Minorities  
 
Members of all races , ethnic groups  and genders  are eligible for this trial.  
 
4.4 Recruitment and Retention Plan  
 
Participants will be recruited through the Pulmonary Clinics at the Denver Veterans Affairs Medical Center and  
by referral from the University of Colorado Hospital  associated clinics .  Subjects who have participated in 
clinical trials carried out through the University of Colorado Specialized Program of Research Excellence  
(SPORE)  in Lung Cancer will be reviewed a nd contacted if they appear to meet entry criteria.  In addition, 
advertisements will be posted at National Jewish Health with study contact information.  During the study, at 
monthly visits, compliance with inhalations will be monitored and subjects will be encouraged to maintain 
compliance .  In order to cover costs to subjects associated with participation on this study, s ubjects will be 
compensated $ 250 at the completion of the second bronchoscopy.  Any participants who have a study biopsy 
with either inv asive carcinoma of the lung or carcinoma in situ will be removed from the study.  
 
5. AGENT ADMINISTRAT ION  
 
Intervention will be administered on an  outpatient  basis.   The initial treatment will be a 2.5 μg inhaled dose 
administered under direct observation  in the clinic ; if this is tolerated, subjects will receive a 5 μg dose per 
treatment thereafter.  Reported adverse events (AEs) and potential risks are described in Section 6.2.  
 
5.1 Dose Regimen and Dose Groups  
 
Iloprost  will be administered 5 μg QID daily for 2 months .   
 
Cohort A: 40 subjects will be enrolled into the QID daily  treatment with iloprost and 1 will be enrolled into the 
QID daily treatment with placebo.  All subjects will be  treated for 60 days.  Study arm assignment  to iloprost or 
placebo  was made in a randomized fashion for the first 7 participants, but then due to unavailability of placebo, 
the remaining partici pants will be assigned to active Iloprost.   
 
NWU2013 -02-01 
Version 3.9, April  19, 201 9 
 
 –16– Cohort B: 5-8 subjects will be  enrolled into the BID daily treatment with iloprost  and 2 were  enrolled into the 
BID daily treatment with placebo .  All subjects will be treated for 60 days.  
 
Cohort A was enrolled to completion  (at the time, 20 subjects)  before initiation of Cohort B enrollment.   After 
an interim analysis, Cohort B was discontinued and Cohort A expanded to 40 subjects  on active agent  (open 
label).  
 
5.2 Iloprost  Administration  
 
Inhaled iloprost  or matched placebo  is delivered by a specialized nebulizer made by Accredo  called the I -neb 
Adaptive Aerosol Delivery (AAD) , which  each subject will be taught to self-administer .  This is the only FDA 
approved device for inhalational iloprost.  It is a lightweight and fully portable device with a rechargeable 
battery.  Each trea tment takes 4 -10 minutes and the device is able to measure compliance  and delivered dose .   
An initial  treatment with a total dose of 2.5 μg iloprost (for those receiving active drug) , or placebo , is given 
under supervision . During this visit the subject w ill be trained on  the proper use of the AAD device.  If clinically 
tolerated, subsequent  doses will be  5 μg.  Intolerance will be defined as coughing lasting more than 10 minutes, 
a systolic blood pressure decrease of more than 20 mm Hg or flushing lasting  more than 10 minutes.   Subjects 
will be given a 5-6 week supply of ampules containing either iloprost or placebo at study visits and will receive 
treatment for 60 days.  We will ask subjects to administer treatments approximately every twelve hours for t he 
BID regimen and approximately every 4 -6 hours while awake for the QID regimen.  
 
5.3 Run-in Procedures   
 
N/A 
 
5.4 Contraindications  
 
None, other than pregnancy or unprotected intercourse for females of childbearing potential, and for males 
having  intercourse with females of childbearing potential  without the use of effective contraception . 
 
5.5 Concomitant Medications  
 
All medications (prescription and over -the-counter), vitamin and mineral supplements, and/or herbs taken by the 
participant will be documented on the concomitant medication CRF and will include: 1) start and stop date, dose 
and route of administration, and  indication.  Medications taken for a test or procedure  (eg. PFT or biopsy) do not 
need to be recorded in CRFs.  
 
5.6 Dose Modification  
 
An initial treatment with a total dose of 2.5 μg iloprost (for those receiving active drug) or placebo is given 
under su pervision and during this visit the subject will be trained on proper use of the I-neb AAD device.  If 
safely tolerated  (intolerance will be defined as coughing lasting more than 10 minutes, a systolic blood pressure 
decrease of more than 20 mm Hg or flush ing lasting more than 10 minutes) , subsequent doses will be 5 μg.  
Participants will be accrued and monitored for toxicity. Toxicity will be graded according to the NCI CTCAE 
version 4.0. If grade 2, 3 or 4 toxicity thought to be at least possibly due to drug is experienced by a subject, 
then modifications based specific doses schedules will be made as follows .  Note 50% dose level indicates  BID 
from QID for Cohort A , and QD from BID for Cohort B.  
 
  Toxicity  Attrib ution to study drug  
Grade  Unrelated  Unlikely  Possible  Probable  Definite  
1  C  C  C  C  C  
2  C  C  S-R0  S-R0  S-R1  
NWU2013 -02-01 
Version 3.9, April  19, 201 9 
 
 –17– 3  S-R2  S-R2  S-R1  W  W  
4  S-R2  S-R2  W  W  W  
C = Continue drug  
S-R0 = Hold  drug until toxicity reaches grade 1 or lower, then restart drug at full dose. If toxicity resumes, hold 
drug again until toxicity reaches grade 1 or lower, and then restart at 50% dose level . No further reductions will 
be permitted and patients with retur ning toxicities will be removed from the study.  
S-R1 = Hold  drug until toxicity reaches grade 1 or lower, then reduce drug by 50% and maintain the reduced 
dose. No further reductions will be permitted and patients with returning toxicities will be removed from the 
study.  
S-R2 = Hold  drug until toxicity reaches grade 1 or lower, then reduce drug by 50% for 2 weeks . If toxicity is no 
more than grade 1, restart drug at full dose.  If toxicity resumes after reintroduction of full dose, hold drug again 
until tox icity reaches grade 1 or lower and then reduce drug by 50% and maintain this dose. No further 
reductions will be permitted and patients with returning toxicities will be removed from the study.  
W = Withdrawal  
 
Participants may miss doses .  Compliance is an outcome measure for this phase I study .  Missed doses will not 
be made up.   Compliance will be assessed at each visit.  For analysis of secondary endpoint responses, we will 
define the efficacy compliance threshold as the initiation of 80% of treatments.    For any Grade 1 toxicities 
(related or unrelated) or unrelated grade 2, 3, or 4 toxicities, subject s will remain on protocol treatment unless 
otherwise directed by the study physician.  
 
5.7 Adherence/Compliance  
 
5.7.1  Compliance  is an outcome measure for this trial, and will be determined at the monthly clinic visit and 
also by interrogating the  I-neb AAD device.   For analysis of secondary endpoint responses, we will define the 
efficacy compliance threshold as the initiation of 8 0% of treatments.  
 
5.7.2  The Accredo  I-neb device measures compliance.  This will be monitored at monthly visits and subjects 
will be encouraged to maintain compliance. Patients will be asked  to keep a study drug diary (see Appendix B). 
We will contact stu dy subjects by phone after 15 days from the first day of agent consumption  to assess 
compliance.    
 
6. PHARMACEUTICAL IN FORMATION  
 
6.1 Study Agent (IND Exempt )   
 
Iloprost ( 5 -{(E)-(1S,5S,6R,7R) -7-hydroxy -6[(E) -(3S, 4RS) -3-hydroxy -4-methyl -1-octen -6-inyl] -bi-
cyclo[3.3.0]octan -3-ylidene}pentanoic acid; Ventavis®) is a synthetic analog of prostacyclin formulated as an 
inhalation solution and approved by FDA for the treatment of pulmonary arterial hypertension (PAH) to 
improve a composite endpoint of exercise tolerance, symptoms, and lack of deterioration. Studies establishing 
effectiveness were performed predominantly in patients with idiopathic or inherited PAH (65%) or PAH 
symptoms associated with connective tissue dis ease (23%). [Ventavis® Prescribing Information 5/2013]  
 
Iloprost Inhalation Solution is a clear, colorless, sterile solution containing iloprost formulated for inhalation via 
the I-neb® AAD® (Adaptive Aerosol Delivery) System. It is supplied in 1 mL single -use glass ampules 
containing 10 µg/mL.  Approximately half the total dose is adequately delivered to the lung, so administration of 
1 mL of the 10 µg/mL  solution results in an effective dose of 5 µg.  
 
Bayer/Actelion will supply Iloprost and Placebo inhalat ion solution ampules to the Denver Veterans Affairs 
Medical Center in coded packaging.  
 
6.2 Reported Adverse Events and Potential Risks  
NWU2013 -02-01 
Version 3.9, April  19, 201 9 
 
 –18–  
Safety data on iloprost inhalation solution were obtained from 215 patients with PH in two 12 -week clinical 
trials and two long -term extensions  19. Patients received inhaled iloprost for periods of from one day to more 
than three years; the median exposure was 15 weeks. Forty patients completed 12 months of open -label 
treatment with iloprost  [Ventavis® Prescribing Information 5/2013].   Inhaled iloprost has not been studied in 
individuals with COPD or severe asthma.  
 
The most common (>3% placebo rate adjusted) adverse events (AEs) noted in the phase 3 registration study 
were vasodil ation (flushing) (18%) ; cough increased (13%); headache (10%); trismus (masticatory muscle 
spasm) (9%); insomnia (6%); nausea, hypotension, vomiting, and alkaline phosphatase increased (each 5%); flu 
syndrome, back pain, and tongue pain (each 4%); and palp itations, syncope, GGT  increased, muscle cramps, 
hemoptysis, and pneumonia (each 3%).  Cases of thrombocytopenia, dizziness, diarrhea, mouth and tongue 
irritation, nasal congestion, dysgeusia (loss of taste), hypersensitivity, and rash have also been reported  
[Ventavis® Prescrib ing Information 5/2013]. Only syncope identified as a serious adverse event (SAE) occurred 
more frequently with inhaled iloprost (5%) than with placebo (0%) among 203 patients19.  These we re not 
associated with clinical deterioration or premature withdrawa l from the study.  
 
SAEs reported in premarketing studies with inhaled iloprost and not included in the most common AE listings  
were congestive heart failure, chest pain, supraventricular t achycardia, dyspnea, peripheral edema, and kidney 
failure. Fatal cas es of cerebral and intracranial hemorrhage have been reported.  
 
In a study in healthy subjects (n=160), inhaled doses of iloprost solution were given every 2 hours, beginning at 
5 µg and increasing up to 20 µg after a total of 6 inhalations (total cumulative dose of 70 µg) or up to the highest 
dose tolerated in a subgroup of 40 subjects. Thirteen subjects (32%) failed to reach the highest scheduled dose 
(20 µg). Five were unable to increas e the dose because of mild to moderate transient chest 
pain/d iscomfort/tightness, usually accompanied by headache, nausea, and dizziness. The remaining eight 
subjects discontinued for othe r reasons  [Ventavis® Prescribing Information 5/2013].  
Inhaled ilop rost may cause bronchospasm, and patients with a history of hyp erreactive airway disease may be 
more sensitive. Inhaled iloprost has not been evaluated in patients with COPD, severe asthma, or acute 
pulmonary infections. In patients with hepatic impairment , the dosing interval may need to be extended 
depending on the subject's response ( e.g., 3−4 hours). Iloprost should not be administered in patients with 
systolic blood pressure below 85 mm Hg, because hypotension leading to syncope has been observed. Ilop rost 
may also cause pulmonary venous hypertension and should be  discontinued if pulmonary edema is present 
[Ventavis® Prescribing Information 5/2013].  
 
A pilot study using an oral tablet formulation of iloprost and a placebo was performed to explore the po tential of 
the drug to improve endobronchial dysplasia in forme r smokers15. A total of 152 subjects (75 iloprost, 77 
placebo) was randomized to one 50 µg tablet bid (100 µg total) or placebo, then escalated  to a maximum of 
three tablets bid (300 µg total) by one additional tabl et per month for a total of six months of treatment. Safety 
was monitored twice during this interval. In the iloprost group, 73% of subjects completed dose escalation 
compared with 89%  of the placebo group (p=0.02). The following AEs were described (and ar e largely identical 
to those reported with inhaled iloprost): headache (52% iloprost vs. 23% placebo), flushing (23% vs. 8%), 
nausea (16% vs. 8%), myalgia (17% vs. 1%), fatigue (11% vs. 2%), neuropathic pain (9% vs. 1%), and 
dysguesia (8% vs. 0%). No SAEs were reported, and there was no significant difference in the number of grade 
3 AEs between groups. Another placebo -controlled trial of oral iloprost (100 or 200 µg bid for six weeks) to 
control Raynaud’s symptoms in systemic sclerosis patien ts reported similar AE rates and types ( e.g., headache, 
flushing, nausea, flu -like syndrome, diarrhea, and trismus)30.   
 
Iloprost has the potential to increase the hypotensive effect of vasodilators and antihypertensive agents. There is 
a potential for increased risk of bleeding, particularly in patients maintained on anticoagulants.  During clinical 
trials, iloprost was use d concurrently with anticoagulants, diuretics, cardiac glycosides, calcium channel 
blockers, analgesics, antipyretics, non-steroidal  anti-inflammatory drugs, corticosteroids, and other medications. 
NWU2013 -02-01 
Version 3.9, April  19, 201 9 
 
 –19– Intravenous infusion of iloprost had no effect on the phar macokinetics of digoxin. Acetylsalicylic acid did not 
alter the clearance (pharmacokinetics) of iloprost  [Ventavis® Prescribing Information 5/2013].  
 
Iloprost has been shown to be teratogenic in rats. In developmental toxicity studies in pregnant Han -Wista r rats, 
continuous intravenous administration of iloprost at a dose of 0.01 mg/kg daily (serum levels not available) led 
to shortened digits of the thoracic extremity in fetuses and pups. In comparable studies in pregnant Sprague -
Dawley rats at oral doses of iloprost clathrate (13% iloprost by weight) up to 50 mg/kg/day (C max of 90 ng/mL), 
in pregnant rabbits at intravenous doses up to 0.5 mg/kg/day (C max of 86 ng/mL), and in pregnant monkeys at 
doses up to 0.04 mg/kg/day (serum levels of 1 ng/mL), no digital anomalies or other gross structural 
abnormalities were observed  fetuses/pups . However, in gravid Sprague -Dawley rats, iloprost clathrate (13% 
ilopros t) significantly increased the number of non -viable fetuses at a maternally toxic oral dose of 250 
mg/kg/day, and it was found to be embryolethal in 15 of 44 litters at an intravenous d ose of 1 mg/kg/day in Han -
Wistar rats.  Fertility of males or females wa s not impaired in Han -Wistar rats at intravenous doses of iloprost up 
to 1 mg/kg/day  [Ventavis® Prescribing Information 5/2013]. There are no adequate, well -controlled clinical 
studies in pregnant women. Inhaled iloprost solution should be used during preg nancy only if the potential 
benefit justifies the potential risk to the fetus.  
 
It is not known whether iloprost is excreted in human milk. In studies with Han -Wistar rats, higher morta lity 
was observed in pups of lactating dams receiving iloprost intraven ously at 1 mg/kg daily. In Sprague -Dawley 
rats, higher  mortality was also observed in nursing pups at a maternally toxic oral dose of 250 mg/kg/day of 
iloprost clathrate (13% iloprost by weight). In rats, passage of low levels of iloprost or metabolites to  milk was 
observed (less than 1% of iloprost dose given intravenously). No disturbance of postnatal development and 
reproductive performance was seen in animals exposed during lactation.  
 
Iloprost was not mutagenic in bacterial and mammalian cells in the presence or absence of extrinsic metabolic 
activation. It did not cause chromosomal aberrations in vitro in human lymphocytes and was not clastogenic in 
vivo in NMRI/SPF mice. There was no evidence of a tumorigenic effect of iloprost clathrate (13% ilopros t by 
weight) in Sprague -Dawley rats dosed orally for up to 8 months at doses up to 125 mg/kg/day (serum C max of 45 
ng/mL), followed by 16 months at 100 mg/kg/day, or in Crl:CD -1®(ICR)BR albino mice dosed orally up to 24 
months at doses up to 125 mg/kg/day (serum Cmax of 156 ng/mL)  [Ventavis® Prescribing Information 5/2013].  
 
In humans, iloprost administered intravenously has linear pharmacokinetics over the dose range of 1 to 3 
ng/kg/min. The half -life is 20 to 30 minutes. Following inhalation of iloprost ( 5 µg), patients with pulmonary 
hypertension have peak plasma levels of approximately 150 pg/mL. Iloprost was generally not detectable in 
plasma 30 minutes to 1 hour after inhalation. The absolute bioavailability of inhaled iloprost has not been 
determined.  Following intravenous infusion, the apparent steady -state volume of distribution was 0.7 to 0.8 L/kg 
in healthy subjects. Iloprost is approximately 60% protein -bound, mainly to albumin, and this ratio is 
concentration -independent in the range of 30 to 300 0 pg/mL. Clearance in normal subjects was approximately 
20 mL/min/kg. The main metabolite is tetranor -iloprost, which is found in the urine in free and conjugated form. 
In animal experiments, tetranor -iloprost was pharmacologically inactive [Ventavis® Prescribing Information 
5/2013].  
 
6.3  Availability  
 
Iloprost inhalation solution and matching placebo will be manufactured and supplied to the Denver Veterans 
Affairs Medical Center  by Actelion Pharmaceuticals US, Inc. (South San Francisco, CA, 94080).  
 
6.4 Agent Distribution  
 
Iloprost solution and placebo will be directly supplied by Bayer/Actelion to the investigators at the Denver 
Veterans Affairs Medical Center.   The Pharmacist at the Denver Veterans Affairs Medical Center will label the 
study medicat ion. 
NWU2013 -02-01 
Version 3.9, April  19, 201 9 
 
 –20–  
6.5  Agent Accountability  
 
The Investigator, or a responsible party designated by the Investigator, will maintain a record of the inventory 
and disposition of all agents received from DCP using the NCI Drug Accountability Record Form (DARF). The 
Investigator will maintain adequate records of receipt, dispensing and final disposition of study agent. This 
respo nsibility has been delegated  to the Denver Veterans Affairs Pharmacy Service, Research Section  (Stephen 
Bartlett) . Include d on receipt record : from whom the agent was received and to whom study agent was shipped, 
date, quantity and batch or lot number. On dispensing record : quantities and dates study agent was dispensed to 
and returned by each participant.  
 
6.6 Packaging and Labeling  
 
Iloprost  solution and matching placebo  will be packaged by  Bayer/Actelion  and sent directly to the Denver 
Veterans Affairs Medical Center .  
 
Iloprost  solution and placebo will be packaged by Actelion Pharmaceuticals .  Cartons  will be labeled with a 
study label containing the study identifier, descriptions of the contents, and instructions and blanks for entering 
the dates of f irst and last use.  The cartons each consist of  30 x 1mL clear glass single -use ampules  that contain 
10 mcg iloprost per 1 mL, or matching  placebo.  The carton will include the sponsor/caution label instructing 
participants that the drug is for investigati onal use only and is to be stored at temperatures between 20°C and 
25°C (68°F and 77°F) and out of the reach of children.   The Research Pharmacy at the Denver Veterans 
Administration Medical Center will provide blinded labeling that will include the Study Numb er, Subject 
Number , and the subject’s initials.  
 
6.7 Storage  
 
Iloprost inhalation solution is supplied in 1 ml clear glass single -use ampules and should be stored in a secure 
location at temperatures between 20°C and 25°C (68°F and 77°F) with excursions permitted to 15°C -30°C 
(59°F -86°F).   Placebo will be provided in a similar ampule, and all investigational ampules will be stored and 
distributed by the Denver VA Research Pharmacy.  
 
6.8 Registration/Randomization  
 
The Lurie Cancer Center Clinical Trials Management System (CTMS) will be the database of record. The study 
coordinator must upload (via CTMS), a signed and complete informed consent along with HIPAA authorization 
and a completed registration form for each participant identified as eligible to be entered into the study.  
 
When possible, the study coordinator will notify an NCPC Quality Assurance M onitor and/or send an email to 
ncpc@northwestern.edu  prior to registering a participant. Prior notification is required for participant 
randomizations outside the normal business hours of Monday -Friday 9:00am -5:00pm CT  Participants must not 
start protocol treatment prior to registration in CTMS.  
 
After the approval of amendment 3.8, t his trial became  a non -randomiz ed trial.   
 
6.9 Blinding and Unblinding Methods  
 
Study participants will receive a prescription, blinded, from the investigatio nal pharmacy at Denver Veterans 
Affairs Medical Center . Unblinding will only occur when it is deemed medically necessary and will only take 
place after consultation with the NCI, DCP Medical Monitor : 
 
DCP Medical  Monitor  
Eva Szabo , M.D., Chief  
NWU2013 -02-01 
Version 3.9, April  19, 201 9 
 
 –21– NCI/Division of Cancer Prevention  
Telephone (240) 276 -7011  
Fax (240) 276 -7848  
Email: szaboe@mail.nih.gov  
 
If the medical monitor is unavailable or if a fter hours consultation is needed, please contact Dr. Seema 
Khan , at telephone:  1-312-503-4236 , or via cell phone : 312 307-3646 .  If Drs. Szabo and Khan are 
unavailable, the research pharmacy may unblind if necessary for patient safety.   In the case of SAEs, 
the investigators should perform what they deem medically appropriate.  
 
6.10 Agent Destruction/Disposal  
 
All drug will be destroyed on site by the Denver pharmacy.   Destruction records will be kept.  
 
NWU2013 -02-01 
Version 3.9, April  19, 201 9 
 
 –22– 7. CLINICAL EVALUATI ONS AND PROC EDURES  
 
7.1 Schedule of Events  
 
 Pre-
screening 
Visit  Screening Visit 
(within 6 
weeks of 
registration  
unless 
otherwise 
noted)  Visit 1 
(Day1)  Phone 
call (Day 
15 +/ - 3 
days)  Visit 2  
(Day 30 
+/-5 
days)  Visit 3  
(day 60 
+/-5 
days)  Visit  4 
(Day 90 
+/-5 
days)  
 Follow 
up1 
Informed Consent  X (Pre -
Screening)  **X (Full 
Consent )        
Inclusion/Exclusion 
Criteria Review  X X       
PHYSICAL          
History and Physical   X   X X X  
Vitals2  X   X X X  
Prior/concurrent 
medication review   X  X X X   
Smoking History   X   X X X  
Performance Status   X   X X X  
Toxicity Assessment    
 X X X X  
 
LABORATORY  
VALUES          
CBC/Platelets 3   X   X X   
Research Blood4  X    X   
Chemistry Panel5  X   X X   
Serum Pregnancy Test6  X    
   
 
MISC. PROCEDURE          
Bronchoscopy/  
Biopsies/ brushings7  X    X   
Sputum8 X *X    X   
Urine (Research)   X    X   
EKG   X9     
  
Full PFT   X    X   
Carbon  Monoxide (CO)   X   X X   
6-Minute Walk Distance   X    X   
Questionnaire s10  X    X   
BODE INDEX   X    X   
 
TREATMENT          
Inhaled Iloprost  
TREATMENT          
Drug Dispensing    X  X    
Ampule Count and I -neb 
download      X X   
Drug Diary    X  X X   
 
                                                      
1 To be done until resolution of all toxicities and then annually (interrogation of National Death Index, Colorado Cancer Registry, and review of electronic medic al record) for 
up to five years from end of treatment.  Follow up should be done per institution's Standard of Care (SOC).  
2 Vitals  to include weight, blood pressure, pulse, respiration rate, and temperature. Height is to be taken only at screening.  
3 Hematology includes assessment of hemoglobin, platelets count, a complete red blood cell count, and total white blood cell co unt (WBC).  
4 Research Blood: Two yellow top citrate s, one purple top EDTA, and one red top tube will be collected.  
5 Serum chemistries include assessment of total serum protein, albumin, bilirubin, AST, ALT, GGT, CO2 , alkaline phosphatase, BUN, creatinine, sodium, potassium, calcium, 
phosphorus, and glucose.  
6 Only applicable to women of child -bearing potential.  
7 Patients are to be called 24 and 72 hours post bronchoscopy to assess for adverse events and instructed to call within 30 day s, if febrile, or with increa sed sputum production, or 
increasing shortness of breath or any perceived deterioration of respiratory condition.   Patient communication log to be completed (Appendix G)  
8To be obtained within three months of registration . *An entry sample will be complete d by subjects who qualify by bronchial dysplasia.  Sputum collection will be performed 
over a six day period or by induction.  
9 Screening EKG to be performed within two months of registration  
10 St. George , CAT , and BORG  questionnaires   
**Signed full trial informed consent to be obtained prior to ordering baseline/screening testing in no specified timeframe prior to registration.  
NWU2013 -02-01 
Version 3.9, April  19, 201 9 
 
 –23– 7.2 Baseline Testing/Pre -study Evaluation  
 
7.2.1  Pre-screening Visit  
 
7.2.1.1  Signed pre -screening informed consent.  
 
7.2.1.2  Sputum cytology:   Sputum cytology will be obtained on enrolled subjects.  Entry consists of two stages, 
with subjects qualifying with either sputum cytologic atypia, or a history of endobronchial dysplasia , 
for the full study.  Qualifying sputum must be submitted less than 3 months prior to bronchoscopy, 
and all subjects will provide an entry sputum sample  (for example, sputum samples will be collected 
from subjects who have a history of endobronchial dyspla sia).  Subjects will be asked to perform an 
early morning sputum collection over a six day period.   Those who are not able to provide spontaneous 
sputum will have a sputum induction with hypertonic saline performed in the Denver VAMC PFT 
laboratory.    The sputum will be collected in a container containing  fixative.  Incoming sputum specimens 
will be processed by a cytotechnologist using the two slide pull technique.  Two slides will be stained by 
the Papanicolaou method and screened by both a cytotechnolog ist and by the study pathologists.  
 
7.2.2  Screening Visit  
 
All screening assessments  below to  be performed within 6 weeks  prior to  registration unless otherwise noted .  
 
1. Signed full trial informed consent  (to be obtained prior to ordering baseline/screenin g testing in no 
specified timeframe prior to registration ). 
 
2. Physical exam  including height, weight, vitals and ECOG performance status.  
 
3. Medical history  including smoking history and concomitant medications . 
 
4. Laboratory analysis  to include: CBC  (hemoglobin, a complete red blood cell  
count, total white blood cell count (WBC) , platelet count , and serum chemistries  (total serum protein, 
albumin, bilirubin, AST, ALT, GGT, CO2 , alkaline phosphatase, BUN, creatinine,   
        sodium, potassium, calcium,  phosphorus, and glucose).  
 
5. Full pulmonary function testing  within 6 months prior to registration . 
   
6. EKG  within 2 months prior to registration . 
 
7. Serum pregnancy  test in females of childbearing potential.  Women are considered to be of child -bearing 
potenti al if they are not surgically sterile or under the age 6 5 and have menstruated within the last two 
years.   
 
8. Exhaled Carbon Monoxide (CO) measurement  
 
9. Six-Minute Walk Distance (6MWD) .  See Appendix C.  
 
10. St. George Respiratory and CAT (COPD Assessment Test) Questionnaire .  See Appendix D and E.  
 
11. BODE Index  will be calculated.   See Appendix F.  
   
12. Blood draw and urine collection  (see section 10 for further  processing details ). 
 
13. Bronchoscopy is scheduled  either at or after this screening visit, unless an autoflu orescence and 
white light bronchoscopy with the full research bronchoscopy procedures and biopsies has been 
performed within 3 months prior to study entry.   Registration will occur after completion of 
bronchoscopy with biopsies, but is not dependent on bio psy results.    
 
NWU2013 -02-01 
Version 3.9, April  19, 201 9 
 
 –24– Bronchoscopy :  Study subjects will undergo autofluorescence (AFB)  and/or white -light  
bronchoscopy prior to starting treatment .    
 
Endobronchial biopsies : Biopsies will be taken from six predetermined sites . In addition, biopsies will be taken 
from any sites that appear suspicious under white light or autofluorescence.     
                                
Endobronchial brushings : The cytology brush es will be placed in a microcentrifuge tube containing 1.0ml  
RNAprotect cell  or RLT+ reagent  or saline  reagent, labeled with a non -identifiable subject ID and time -point 
(enrollment or post -treatment), snap -frozen in liquid nitrogen and stored at < -80C.  
                    
Research Blood : Two yellow top citrate s, one purple top EDTA, and one red top  tube will be collected  and stored 
for later analysis .   
 
Urine collection :  Urine will be collected and adjusted to a final concentration of 2N glacial acetic acid  
and stored at –80  C. 
 
Sputum cytology:   Subjects who qualify by bronchial dysplasia will complete an entry sputum sample.   Subjects 
will be asked to perform an early  morning sputum collection over a six day period.   Those who are  unable to 
provide spontaneous sputum (or who have an unsatisfactory specime n) will have a sputum induction with 
hypertonic saline performed in the  Denver VAMC PFT laboratory.    
 
All screening assessments must be completed prior to registration . 
 
7.3 Evaluation During Study Intervention  
 
7.3.1 Visit 1  (Day 1)  
 
After all eligibilit y criteria confirms the subject eligible to participate in this study, the patient will be registered .   
The study drug will be dispensed at Visit 1.  The instructions will be reviewed with the participant, the first dose 
will be taken, and the participant  will be observed for 30 minutes.   Patients will be given a drug diary and instructed 
to complete daily.  
 
7.3.2  Day 15  Phone call (+/ - 3 days)  
 
Patients will receive a telephone call to review compliance and side effects.  
 
7.3.3 Visit 2  (Day 30 [+/- 5 days ]) 
 
1. Physical exam  including weight, vitals and ECOG  performance status.  
 
2. Medical history  including smoking history and concomitant medications  
 
3. Laboratory analysis  to include: CBC, platelet count , and serum chemistries  (total serum  
       protein, albumin, bilirubin, AST, ALT, GGT, CO2 , alkaline phosphatase, BUN, creatinine,   
      sodium, potassium, calcium, phosphorus, and glucose).   
   
4. Exhaled Carbon Monoxide (CO) measurement  
 
5. Toxicity Assessment  
 
6. Ampule count  and diary review.  
 
7. Interrogation of I -neb AAD device to determine compliance.   Accredo has developed software that 
interfaces with the AAD device and can provide dosing information.  
NWU2013 -02-01 
Version 3.9, April  19, 201 9 
 
 –25–  
8. Drug dispensing.  
 
7.4 Evaluation at Completion of Study Intervention  
 
7.4.1 Visit 3  (Day 60 [+/- 5 days ]) 
 
1. Physical exam  including weight, vitals and ECOG  performance status.  
 
2. Medical history  including smoking history and concomitant medications  
 
3. Laboratory analysis  to include: CBC, platelet count , and serum chemistries  (total serum  
      protein, albumin, bilirubin, AST, ALT, GGT, CO2 , alkaline phosphatase, BUN, creatinine,   
     sodium, potassium, calcium, phosphorus, and glucose).  
 
4. Full pulmonary function testing  
  
5. Exhaled Carbon Monoxide (CO) measurement  
 
6. Ampule count  and diary review.  
 
7. Interrogation of I -neb AAD device to determine compliance.  
 
8. Six-Minute Walk Distance (6MWD).  See Appendix C.  
 
9. St. George Respiratory and CAT (COPD Assessment Test) Questionnaire.  See Appendix D and E.  
 
10. BODE Index will be calculated.  See Appendix F.  
 
11. Research Blood: Two yellow top citrate s, one purple top EDTA, and one red top tube will be collected 
and stored for later analysis.   
 
12. Bronchoscopy, sputum, and urine collection  (see section 10 for further  processing details).  
 
Note that Visit 3 may be completed over a two -day time frame as long as all testing remains within the protocol 
specified time frame for Visit 3 (Day 60+/ - 5days).  
Bronchoscopy :  Study subjects will undergo autofluorescence  and/or white -light bronchoscopy . 
 
Endobronchial biopsies : Biopsies will be taken from six predetermined sites .  In addition, biopsies will be taken 
from any sites that appear suspicious under white light or fluorescence.  
                                
Endobronchial brushings : Cytology brush es will be placed in a microcentrifuge tube containing 1.0 ml  
RNAprotect cell  reagent  or RLT+ reagent  or saline , labeled with a non -identifiable subject ID and time -point 
(enrollment or post -treatment), snap -frozen in liquid nitrogen and stored at < -80C.  
 
Research Blood :  Two yellow top citrate s, one purple top EDTA, and one red top  will be collected.  
 
Urine collection :  Urine will be collected and adjusted to a final concentration of 2N glacial acetic acid  
and stored at –80  C. 
 
Sputum cytology:   Sputum cytology will be obtained.  Subjects will be asked to perform an early morning  
sputum collection over a six day period  immediately after the 60 day study visit .   The sputum will be collected  
in a container with  fixative.  Incoming sputum specim ens will be processed b y a cytotechnologist using the two 
slide pull technique.  Two slides will be stained by the Papanicolaou method and screened by both a 
cytotechnologist and by the study pathologists.  
 
NWU2013 -02-01 
Version 3.9, April  19, 201 9 
 
 –26– 7.5 Post-intervention Follow -up Period  
 
7.5.1 Visit 4 (Post-intervention Day 90 [+/- 5 days])  
 
1. Physical exam  including weight, vitals and ECOG  performance status.  
 
2. Medical history  including smoking history and concomitant medications  
 
3. Toxicity Assessment  
 
7.5.2  Follow up  
 
Patients who have developed drug-related toxicities will have follow -up clinic visits  per institutional SOC  until 
the toxicity resolves.    
 
7.6 Methods for Clinical Procedures  
 
Bronchoscopy :   Study subjects will undergo autofluorescence and white -light bronchoscopy . 
 
Endobronchial biopsies : Biopsies will be taken from six predetermined sites  as described in 10.2 .  In addition, 
biopsies will be taken from any sites that appear suspicious under white light or fluorescence.  
                                
Endobronchial brushings : Cytology brushes will be placed in a microcentrifuge tube containing 1.0 ml  
RNAprotect cell  reagent  or RLT+ reagent  or saline , labeled with a non -identifiable subject ID and time -point 
(enrollment or post -treatment), snap -frozen in liquid nitrogen and s tored at < -80C.  
 
Research Blood:   Two yellow top citrate s, one purple top EDTA, and one red top  will be collected.  
 
Urine collection :  Urine will be collected and adjusted to a final concentration of 2N glacial acetic acid  
and stored at –80  C. 
 
Sputum cytology:   Sputum cytology will be obtained.  Subjects will be asked to perform an early morning  
sputum collection over a six day period.   The sputum will be collected in a container with  fixative.  Incoming 
sputum specimens will be processed by a cytot echnologist using the two slide pull technique.  Two slides will be 
stained by the Papanicolaou method and screened by both a cytotechnologist and by the study pathologists.  
 
8.  CRITERIA FOR EVA LUATION AND ENDPOINT  DEFINITION  
 
8.1 Primary Endpoint  
 
Toxicity data for participants according to active drug (iloprost)  will be collected.  
 
8.2 Secondary Endpoints  
 
Secondary Endpoints will be evaluated in a batch fashion analyzed once the targeted number of study subjects 
has completed the protocol.  
 
8.3 Off-Agent Criteria  
 
Participants may stop taking study agent for the following reasons: completed the protocol -prescribed 
intervention, adverse event or serious adverse event, inadequate agent supply, noncompliance, concomita nt 
medications, and medical contraindication.   If screening biopsy shows either invasive carcinoma or carcinoma in 
situ, the participant will be taken off study and managed according to participant and physician decision.  
NWU2013 -02-01 
Version 3.9, April  19, 201 9 
 
 –27– Participants will continue to be f ollowed, if possible, for safety reasons and in order to collect endpoint data 
according to the schedule of events.  Patients will not be replaced.  
 
8.4 Off-Study Criteria  
 
Participants may go ‘off -study’ for the following reasons:  
 
 Adverse Event  
 Death  
 Disease Progression  
 Discovery of invasive carcinoma or carcinoma in situ on screening biopsy  
 Lost to follow -up 
 Other  
 Participant Withdrawal  
 Participant Refused Follow -up 
 Physician Decision  
 Protocol Defined Follow -up Completed  
 Protocol Violation   
 Study Complete  
 Ineligible  
  
8.5 Study Termination  
 
NCI, DCP as the study sponsor has the right to discontinue the study at any time.  
 
9. CORRELATIVE/SPECI AL STUDIES  
 
9.1 Rationale for Methodology Selection  
 
A number of exploratory secondary endpoints wil l be assessed to guide future chemoprevention studies.  
 
Endobronchial histology :  Oral iloprost administration resulted in improvement in endobronchial histology in 
former smokers14.  We will utilize the same procedures for tissue acquisition, fixation and  pathologic 
examination as described.  
 
Effect on serum proteins : An exploratory analysis of the association of serum protein abundance with baseline 
dysplasia revealed six proteins ( ADIPOQ, C9, ATP5B, CHST15, SHBG, HNRNPA2B1) with the potential to 
predict endobronchial dysplasia.  These were quantitated using a highly multiplexed aptamer based assay system 
developed by SomaLogic, Inc .16.  The current study provides an opportunity to validate these associations, 
potentially leading to a means to identify hig h risk individuals with bronchial dysplasia non -invasively.  
 
Effect on endobronchial brushing and biopsy genomics : Endobronchial brushings have previously been reported 
as potential predictive biomarkers for chemoprevention response to myo -inositol28.  We propose to carry out 
exploratory analyses of gene expression biomarkers for chemopreventive response to inhaled iloprost.  Dr. 
Daniel Merrick has analyzed gene expression patterns discriminating dysplastic lesions that persist or progress 
from those that r egress spontaneously, with the identification of a 46 gene predictive panel.  We propose to test 
whether this predictive panel can be validated in this Phase I inhaled iloprost study.  In addition, DNA from 
bronchial epithelial samples will be stored for fu ture analysis of somatic mutations.  
 
Parameters of COPD severity :  COPD shares a major causative agent (tobacco smoke) with lung cancer and is a 
biomarker for risk of developing lung cancer31.  Ideally, lung cancer chemopreventive agents would also have 
beneficial effects on COPD.   Iloprost has anti -inflammatory properties and may potentially modulate lung 
NWU2013 -02-01 
Version 3.9, April  19, 201 9 
 
 –28– function.  Inhaled iloprost improves V/Q matching, reduces pulmonary hypertension and could have a favorable 
effect on patients with COPD32.  We propose  exploratory analysis of pulmonary function, 6 minute walk test and 
quality of life measurements, similar to those being carried out in a current Phase II pioglitazone 
chemoprevention trial.  
 
The conduct of early phase cancer trials provides the opportunity to evaluate systemic drug effect markers.  
Clinical samples will therefore be captured and stored for purposes of future molecular fingerprinting at the 
level of both the proteome as well as  at the level of gene expression (i.e. RNA) from blood samples.  Therapy -
induced changes in cellular function will be expected to result from changes in gene expression and/or protein 
expression.  Advances in technology now permit protein and expressed gen e (RNA) compartments to be 
analyzed on a broad scale, or to be fingerprinted.  Pre - and post -treatment plasma and RNA from peripheral 
white blood cells will therefore be collected and stored for future batch analysis.  Blood plasma proteins will be 
charact erized by mass spectrometric analysis, while expressed genes will be characterized by using RNA to 
probe gene arrays.  Samples will be banked, for future processing. Resultant data relating to the molecular 
effects of this drug, as well as future drugs, wi ll be used to populate a library.  This data library, which will not 
have any patient identifier information in it, will contain information which will cross classes of drugs, as well 
as target cohorts (i.e., cohorts at risk for different cancer types).   
 
9.2 Comparable Methods  
 
Endobronchial histology :  The methods proposed for tissue processing and pathologic grading are the only ones 
to have previously successfully demonstrated improvement in endobronchial histology with a chemopreventive 
agent, oral iloprost.  
 
Effect on serum proteins : The aptamer based highly multiplexed protein assay system developed by SomaLogic, 
Inc. is highly sensitive and reproducible, with a mean limit of detection of 40 fM.  At a cost of $300 per patient 
(pretreatment and post  treatment samples), this is a highly cost effective assay.  
 
Effect on endobronchial brushing and biopsy gene expression :  RNA sequencing , DNA sequencing, and gene 
promoter methylation  will be used for these assays.  In order to discriminate between somati c and germ line 
mutation, DNA sequencing will be performed on peripheral blood DNA in selected instances.   
 
Parameters of COPD severity :  Full PFTs, 6 minute walk test, and the St. George ’s respiratory questionnaire and 
COPD assessment test are all well r ecognized standard tests that can be reproducibly performed either in the 
Denver VAMC Pulmonary Function Laboratory or by our study coordinators.  
 
10. SPECIMEN MANAGEM ENT  
 
10.1 Laboratories  
 
10.1.1. Tissues for study specific biomarkers  
 
Specimens will be  processed and banked at the SPORE Tissue Bank located on the University of Colorado 
Anschutz Medical Campus.    
 
The address is:   
SPORE Lab  
University of Colorado Denver  
RC1 South  
12801 E. 17th Avenue Room L18 -5400F  
Aurora, CO 80045  
 
NWU2013 -02-01 
Version 3.9, April  19, 201 9 
 
 –29– Specimens for blood sample laboratory analysis for the Screening visit, and Visits 2 and 3  will be analyzed at:  
Denver Veterans Administration Medical Center  
Department of Pathology and Lab Medicine  
1055 Clermont Street, #113  
Denver, CO 80220  
 
10.1.2. Tissue Banking  
All biosp ecimens will be considered the property of the National Cancer Institute and will not be used for assays 
other than specified in this protocol without NCI approval.   Biospecimens will be stored in the University of 
Colorado SPORE Tissue Bank, a Department of Veterans Affairs approved tissue bank, and supplied to the 
National Cancer Institute as needed after approval of supplemental amendments.  Plasma from blood and DNA  
from peripheral white blood  cells, will be collected at baseline (just prior to treatmen t), and at the end of 
treatment, and will be stored  in the SPORE Tissue Bank  for future proteomic and genetic analysis . This analysis 
will be performed in the future, and will seek to evaluate the effects of therapeutic intervention by comparing 
pre- and p ost-treatment samples, and measuring changes in protein expression and epithelial mutation .  Samples 
will be de -identified through established SOPs no information will be conveyed back to individual subjects, nor 
will any link to individual subjects be sou ght. 
  
10.2 Collection and Handling Procedures  
  
Bronchoscopy :  Study subjects will undergo autofluorescence and /or white -light bronchoscopy after being NPO 
for a minimum of six hours prior to the procedure. The patient will be monitored with continuous 
electrocardiographic, respiratory and oximetric monitoring, and with intermittent blood pressure monitoring.  A 
complete endobronc hial inspection will be performed and suspicious areas identified under fluorescence or 
white light will be biopsied.  A Bronchoscopy Patient Communication Log Form is attached (Appendix G) to 
follow -up the patients after the bronchoscopy is performed.  Pa tients are called within 24 hours, 72 hours,  and 
instructed to call within 30 days, if febrile, or with increased sputum production, or increasing shortness of 
breath or any perceived deterioration of respiratory condition.  
 
Endobronchial biopsies: Biopsie s will be taken from six predetermined sites:  upper lobe orifices and superior 
segment orifices (left and right), carina between left upper lobe division and lingular orifices and right middle 
lobe orifice.  In addition, biopsies will be taken from any sites that  appear suspicious under white light or 
fluorescence.  On follow -up bronchoscopies, all sites from the original bronchoscopy will be rebiopsied, along 
with any abnormal appearing areas under white light or fluorescence.  Biopsies will be formalin -fixed and 
paraffin -embedded for hematoxylin and eosin staining, as well as for immunohistochemical staining.  One or 
more biopsies may be cultured or snap frozen for protein, RNA or DNA analysis.  Depending on patient 
tolerance , and operator discretion, end obronchial biopsies may be terminated at any time; however, an attempt 
will be made to biopsy between  6 and 12 sites on each patient.  Additional sites may be biopsied if deemed 
clinically indicated but more than  12 endobronchial biopsies will not be routi nely taken.  The number and 
location of biopsies may be altered according to bronchoscopist’s di scretion and patient tolerance .                                
Endobronchial brushings: Endobronchial brushings will be taken from either the right and/or left, usually 
corresponding with certain  biopsy  sites (normal and abnormal appearing areas) .  Additionally, the right 
mainstem bronchus will be brushed when possible, or if not a possibility, a brushing will be completed in the 
left mainstem bronchus .  Cytology brushes will be placed in a microcentrifuge tube containing 1 ml RNA protect 
cell reagent  or RLT+ reagent  or saline , labeled with a non -identifiable subject ID and time -point (enrollment or 
post-treatment), snap -frozen in liquid nitrogen and stored  at <-80ºC.  The number and location of brushings  may 
be altered according to bronchoscopist’s di scretion and patient tolerance.  
 
Research Samples for Biomarkers :  Two yellow top citrate s, one purple top EDTA, and one red top  tube will 
be collected  and banked for future studies . 
 
NWU2013 -02-01 
Version 3.9, April  19, 201 9 
 
 –30– Two 8.5 ml Vacutainer Citrate (yellow top) tube s.  Draw blood into tubes and immediately mix thoroughly with 
anticoagulant by gently shaking.   Refrigerate immediately until transfer to processing lab.   Upon arrival at 
processing lab, centrifuge both tubes at 400 x G for 20 minutes. Remove the buffy coat from one tube (approx 
1ml) to a 2ml bar -coded cryovial. Remove the buffy coat from the second tube (approx 1ml) to a 2ml bar -coded 
cryovial and add 700ul RLT+ reagent (Q iagen, cat. 1053393). Invert several times to mix. Freeze both buffy 
coat vials immediately. Remove the plasma remaining in each tube and place in individual 15mL conical vials. 
Centrifuge the conical vials at 4000 rpm for 10 minutes, and aliquot the spun plasma into 0.5mL bar -coded 
cryovials, as many as the sample allows, a maximum of 10 per tube. Plasma must be clear before freezing; no 
cells or debris should be present.   Freeze all immediately at –80C.  
 
One 10.0 ml  Vacutainer Serum (red top) tube.  Draw blood into tube and immediately mix thoroughly by 
inverting 8 to 10 times. Allow clot formation for 30mins at room temp.  Centrifuge at 4000 rpm for 10 mins at 
room temp.  
 
Urine collection:   
Urine will be collected a screw -top jar and aliquoted into six 3  ml cryovials.   Any remaining urine is to be 
discarded.   Seal the cap tightly.   Freeze urine sample at –80˚C for future studies.  
 
Sputum cytology:  Sputum cytology will be obtained.  Subjects will be asked to perform an early morning  
sputum collection ove r a six day period.   For those unable to provide a spontaneous expectorated specimen, 
sputum induction with hypertonic saline will be performed in the DVAMC PFT lab.    The sputum will be 
collected in a container containing fixative.  Incoming sputum specim ens will be processed by a 
cytotechnologist using the two slide pull technique.  Two slides will be stained by the Papanicolaou method and 
screened by both a cytotechnologist and by the study pathologists.  
 
One 10.0 ml EDTA Vacutainer (purple top) tube.  Collect 10ml of peripheral blood for gene array analysis . 
Draw blood into tube and immediately mix thoroughly with anticoagulant by gently shaking.   Refrigerate 
immediately until transfer to processing lab.   Upon arrival at processing lab, centrifuge at 40 0 x G for 20 
minutes.     Remove the buffy coat ACD tubes (approx 1ml) to a 2ml bar -coded cryovials.   Remove the plasma 
remaining and place in a 15mL conical vial. Centrifuge the conical vial at 4000 rpm for 10 minutes, and aliquot 
the spun plasma into 0.5m L bar -coded cryovials, as many as the sample allows, a maximum of 10. Plasma must 
be clear before freezing; no cells or debris should be present.   Freeze all immediately at –80C. 
 
10.3 Research Samples for Genetic/ Genomic Analysis:  
 
10.3.1  Description of the scope of genetic/ genomic analysis  
 
RNA sequencing,  DNA sequencing , and gene promoter methylation will be performed on samples from selected 
airway biopsies and brushings. In order to discriminate between somatic and germ line mutation,  DNA 
sequencing will be performed on peripheral blood DNA in selected instances.   
 
10.3.2 Description of how privacy and confidentiality of medical information/biological specimens will be 
maximized  
 
All tissue and blood samples collected under this study will be coded . DNA and RNA  isolated from these 
tissues  will all be similarly coded. Only the site Principal Investigator and primary research coordinators 
involved with  this study  at the University of Colorado will have access to  the code .  
 
To facil itate genetic research, and for the purpose of publication of research work, data from genetic and 
genomic studies may be deposited in appropriate public databases. Coded data will be deposited in a 
manner that the patient’s identity cannot be traced and p atients will have the opportunity to opt out of 
having their information deposited in appropriate public databases at the time of informed consent.  
NWU2013 -02-01 
Version 3.9, April  19, 201 9 
 
 –31–  
10.3.3 Management of Results  
 
The analyses performed in University of Colorado and National Jewish Health laboratories under this 
protocol are for research purposes only; they are not nearly as sensitive as the tests that are performed in a 
laboratory that is certified to perform genetic testing for clinical purposes  and are not meant to substitute 
for clinica l care at any time . Changes observed unrelated to our research may or may not be valid. 
Therefore, we do not plan to inform participants of the results of testing on the tissue or blood that is 
performed in research labs.  
 
However, in the unlikely event t hat clinically relevant incidental findings are discovered, subjects will be 
contacted if a clinically actionable gene variant is discovered. Clinically actionable findings for the purpose 
of this study are defined as disorders appearing in the American Co llege of Medical Genetics and 
Genomics recommendations for the return of incidental findings that is current at the time of primary 
analysis. (A list of current guidelines is maintained on the CCR intranet: 
https://ccrod.cancer.gov/confluence/display/CCRCRO/Incidental+Findings+Lists ). Subjects who still 
remain on the study will be contacted by the site Principal Investigator and be  provided with a  referral to a 
certified genetic health professional if the subject desires. Any costs associated with follow -up of a n 
actionable gene variant will be responsibility of the subject.  
 
This is the only time during the course of the study that incidental findings will be return ed. No 
interrogations regarding clinically actionable findings will be made after the primary analysis.  
 
10.4 Shipping Instructions  
 
None.  All samp les will be stored and processed  on site.   
 
10.5 Tissue Banking  
 
Biospecimens are collected either immediately prior to bronchoscopy or during bronchoscopy and stored in the 
Colorado SPORE in Lung Cancer Tissue Bank and Biomarkers Core (TBBC) according to established standard 
operating procedures (SOPs).  
 
Biologic specimens collected during the conduct of each clinical trial that are not used during the course of the 
study will be considered deliverables under the contract and thus the property of the NCI. At study completion, 
NCI reserves the option to either retain or relinquish ownership of the unused  biologic specimens .  If NCI 
retains ownership of specimens, the Contractor shall collect, verify and transfer the requested biologic 
specimens from the site to a NCI -specified repository or laboratory at NCI’s expense , provided that this is a VA -
approved tissue bank .  If no such VA -approved tissue bank is identified, specimens will remain in the SPORE 
Tissue Bank for future distribution.   
 
11. REPORTING ADVERS E EVENTS  
 
DEFINITION: AE means any untoward medical occurrence associated with the use of a drug in humans, 
whether or not considered drug related. An AE can therefore be any unfavorable and unintended sign), 
symptom, or disease temporally associated with participation in a study, whether or not related to that 
participation. This includes all deaths that occur while a participant is on a study.  
 
Please note that all abnormal clinical laboratory values that are determined to be of clinical significance based 
on a physician’s assessment are to be reported as AEs. Those labs determined to be of no clinic al significance or 
of unknown clinical significance (per the physician’s assessment) should not be reported as AEs. Any lab value 
NWU2013 -02-01 
Version 3.9, April  19, 201 9 
 
 –32– of unknown clinical significance should continue to be investigated/followed -up further for a final 
determination, if possible , by the treating physician’s discretion . 
 
A list of AEs that have occurred or might occur (Reported Adverse Events and Potential Risks) can be found in 
§6.2, Pharmaceutical Information, as well as the Investigator Brochure or package insert.  
 
11.1 Advers e Events  
 
11.1.1  Reportable AEs  
 
All AEs that occur after the informed consent is signed and baseline assessments are completed must be 
recorded on the AE CR F (paper and/or electronic) whether or not related to study agent.  
11.1.2  AE Data Elements:  
 
The following data elements are required for adverse event reporting.  
 AE verbatim term  
 System Organ Class (SOC)  
 Common Terminology Criteria for Adverse Events v4.0 (CTCAE) AE term  
 Event onset date and event ended date  
 Severity grade  
 Attribution to study agent (relatedness)  
 Whether or not the event was reported as a serious adverse event (SAE)  
 Whether or not the subject dropped due to the event  
 Outcome of the event  
 
11.1.3  Severity of AEs  
   
11.1.3.1   Identify the AE using the NCI Common Terminology Criteria fo r Adverse Events (CTCAE) 
version 4.0. The CTCAE provides descriptive terminology and a grading scale for each adverse event listed. A 
copy of the CTCAE can be found at http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm  
 
AEs will be assessed according to the CTCAE grade associated with the AE term. AEs that do not have a 
corresponding CTCAE term will be assessed according to the general guidelin es for grading used in the CTCAE 
v4.0. as stated below.  
 
CTCAE v4.0 general severity guidelines:  
 
Grade  Severity  Description  
1 Mild  Mild; asymptomatic or mild symptoms; clinical or diagnostic 
observations only; intervention not indicated.  
2 Moderate  Moderate; minimal, local or noninvasive intervention indicated;  
limiting age -appropriate instrumental activities of daily living 
(ADL)*.  
3 Severe  Severe or medically significant but not immediately life -threatening;  
hospitalization or prolongation of hosp italization indicated; 
disabling; limiting self -care ADL**.  
4 Life-threatening  Life-threatening consequences; urgent intervention indicated.  
5 Fatal  Death related to AE.  
   
ADL  
 
NWU2013 -02-01 
Version 3.9, April  19, 201 9 
 
 –33– *Instrumental ADL refers to preparing meals, shopping for groceries or clothes, using the telephone, managing 
money, etc. 
 
**Self -care ADL refers to bathing, dressing and undressing, feeding self, using the toilet, taking medications, 
and not bedridden.  
 
11.1.4  Assessment of relationship of AE to treatment  
  
The possibility that the adverse event is related to study agent will be classified as one of the following: not 
related, unlikely, possible, probable, definite.  
  
11.1.5  Follow -up of AEs  
 
All AEs, inc luding lab abnormalities that in the opinion of the investigator are clinically significant, will be 
followed according to good medical practices and documented as such.   If a participant is taken off study due to 
discovery of invasive carcinoma or carcino ma in situ, these participants will be followed according to standard 
of care.  
 
11.2 Serious Adverse Events  
 
11.2.1  DEFINITION: Fed. Reg. 75, Sept. 29, 2010 defines SAEs as those events, occurring at any dose, which 
meet any of the following criteria:  
 Results in death  
 Is life threatening ( Note: the term life -threatening refers to an event in which the patient was at risk of 
death at the time of the event; it does not refer to an event which hypothetically might have caused death 
if it were more severe).  
 Requires inpatient hospitalization or prolongation of existing hospitalization  
 Results in persistent or significant incapacity or substantial disruption of the ability to conduct normal 
life functions  
 Is a congenital abnormality/birth defect  
 Important medi cal events that may not result in death, be life -threatening or require hospitalization may 
be considered serious when, based upon appropriate medical judgment, they may jeopardize the patient 
or subject and may require medical or surgical intervention to prevent one of the outcomes listed.  
 
11.2.2  Reporting SAEs to DCP  
 
11.2.2.1   The Lead Organization and all Participating Organizations will report SAEs on the DCP SAE 
form found at http://prevention.cancer.gov/sites/default/files/uploads/clinical_trial/SAE -Form.pdf . 
 
11.2.2.2   Contact the DCP Medical Monitor  by phone or email within 24 hours of knowledge of the 
event.  
 
DCP Medical Monitor  
Eva Szabo , M.D.  
Chief, LUACRG, DCP, NCI 
9609 Medical Center Dr., Rm 5E -102, MSC 9781  
Bethesda, MD 20892 -9781 (for FedEx , use Rockville, MD 20850)  
Telephone (240) 276 -7011  
Fax (240) 276 -7848  
Email: szaboe@mail.nih.gov  
 
Include the following information when calling the Medical Monitor : 
NWU2013 -02-01 
Version 3.9, April  19, 201 9 
 
 –34–  Date and time of the SAE  
 Date and time of the SAE report  
 Name of reporter  
 Call back phone number  
 Affiliation/Institution conducting the study  
 DCP protocol number  
 Title of protocol  
 Description of the SAE, including attribution to drug and expectedness  
 
11.2.2.3   The Lead Organization and all Participating Organizations will email  written SAE reports to the 
DCP Medical Monitor  within 48 hours of learning of the event using the paper SAE form. The written SAE 
reports will also be emailed (safety@ccsainc.com)  to DCP’ s Regulatory Cont ractor, CCS Associates (phone: 
650-691-4400).  The written SAE reports will also be emailed ( ncpc @northwestern.edu ) to the Lead 
Organization (phone: 312 -695-0562) if sent by a Participating O rganization.   
 
SAEs that are a response to the medicinal product should be reported to Bayer Actelion ( email: 
DrugSafety.GPV.US@bayer.com , phone: 1 -888-842-2937).   The accrual site is responsible for determining 
which SAEs should be reported to Bayer Actelion.  
  
11.2.2.4   The DCP Medical Monitor  and regulatory staff will determine which SAEs require FDA 
submission.  
 
11.2.2.5   The Lead Organization and all Participating Organizations will comply with applicable 
regulatory requirements related to reporting SAEs to the IRB/IEC.  
 
11.2. 3 Follow -up of SAE  
 
Site staff should send follow -up reports as requested when additional information is available. Additional 
information should be entere d on the DCP SAE form in the appropriate format. Follow -up information should 
be sent to DCP as soon as available. Follow up information should be sent to the DCP and Lead Organization as 
soon as available.  
 
12. STUDY MONITORING  
 
12.1 Consortia 2012 Data Management  
 
Data will be managed by the study statistician, Dr. Jovanovic, according to standard operating procedures, 
which meet the guidelines of DCP Requirements for Data Management and which follow the Data Management 
Plan that Northwestern University has on file with the Division of Cancer Prevention, NCI.    The Consortia 
2012 Data Management Plan, submitted as part of a contract agreement with the NCI (HHSN261201200035I), 
was approved.  
 
12.2 Case Report Forms  
 
Participant data will be collected using  protocol -specific case report forms (CRFs) developed from the standard 
set of DCP Chemoprevention CRF Templates and utilizing NCI -approved Common Data Elements (CDEs). The 
approved CRFs will be used by Northwestern University  to create the electronic CRFs  (e-CRFs) screens in the 
Lurie Cancer Center Clinical Trials Management System . Site staff will enter data into the e -CRFs for 
transmission to DCP according t o DCP standards and procedures.  
 
12.3 Source Documents  
 
NWU2013 -02-01 
Version 3.9, April  19, 201 9 
 
 –35– All source documents will be collected and stored at the study site.  Any data recorded directly on CRFs that 
constitute no prior written or electronic record of data, will be specifically identified as source data.  
 
12.4 Data and Safety Monitoring Plan  
 
A comprehensive Data Safety and Monitoring Plan has been submitted by Northwestern University, has been 
approved by the DCP, and is on file there.  Any future changes will be forwarded for review .   
 
12.5 Sponsor , FDA , or Biomarker Development Partner  Moni toring  
 
The NCI, DCP (or their designee), pharmaceutical and technology collaborator (or their designee), or FDA may 
monitor/audit various aspects of the study. Collaborators with a research agreement with the University of 
Colorado (the enrollment site) m ay also monitor/ audit various aspects of the study. These monitors will be 
given access to facilities, databases, supplies and records to review and verify data pertinent to the study.  
 
12.6 Record Retention  
 
Clinical records for all participants, including CRFs, all source documentation (containing evidence to study 
eligibility, history and physical findings, laboratory data, results of consultations, etc.), as well as IRB records 
and other regulatory documentation , will be retained by the Investigator in a secure storage facility in 
compliance with Health Insurance Portability and Accountability Act (HIPAA), Office of Human Research 
Protections (OHRP), Food and Drug Administration (FDA) regulations and  guidances, and NCI/DCP 
requirements, unless the standard at the site is more stringent. The records for all studies performed under an 
IND will be maintained, at a minimum, for two years after the approval of a New Drug Application (NDA). For 
NCI/DCP, rec ords will be retained for at least three years after the completion of the research. NCI will be 
notified prior to the planned destruction of any materials. The records should be accessible for inspection and 
copying by authorized persons of the Food and D rug Administration. If the study is done outside of the United 
States, applicable regulatory requirements for the specific country participating in the study also apply.  
 
12.7 Cooperative Research and Development Agreement (CRADA)/Clinical Trials Agreement  (CTA)/ 
Material Transfer Agreement (MTA)/ Master Research Agreements  
 
Agreements  will be negotiated between the University of Colorado and Bayer/Actelion as well as Accredo . An 
additional M aster Research Agreement has been  negotiated between the Universit y of Colorado and VisionGate, 
Inc. to allow for use of sputa samples for analysis by automated three dimensional morphologic analysis.  
 
13. STATISTICAL CONS IDERATIONS  
 
13.1 Study Design/Description  
 
This is a Phase I toxicity and compliance study.  The pri mary endpoints are clinical toxicity and compliance.  
Secondary endpoints are the response of airway histology, serum protein profiling, endobronchial brushing gene 
expression and gene expression of dysplastic lesions.  
 
13.2 Randomization/Stratification  
 
This is an open label trial. We initially proposed to study two separate iloprost dosing regimens (QID and BID) 
with 20 enrolled subjects in each iloprost dosing regimen group (estimated attrition of 20% during the study 
would result in 16 evaluable partic ipants per group). In Cohort A, the first 7 subjects were randomized to 
iloprost versus placebo, with one participant receiving placebo, but the remaining 14 subjects will not be 
randomized and instead will be given active iloprost. This is due to lack of availability of the placebo. Within 
the BID group (Cohort B), we randomized 4 participants, until revision for protocol v3.8 was  approved, due to 
NWU2013 -02-01 
Version 3.9, April  19, 201 9 
 
 –36– the expiration of placebo in December 2018. After approval of protocol v3.8, we registered all proceeding 
participants to cohort B as open label (without randomization). Thus, 7 participants were enrolled to cohort B: 5 
active treatment B ID, and 2 placebo. During the approval of protocol v3.9, we expect that up to 3 more patients 
will be enrolled into Cohort B open label. Thus, we expect Cohort B will have 5 -8 patients on active agent, and 
2 patients on placebo.  
 
An interim analysis was c onducted after completion of Cohort A and discussed on March 26, 2019.  As toxicity 
was minimal with the QID regimen and compliance was good (65% achieved 80% compliance or more), a 
decision was made to discontinue Cohort B and enlarge Cohort A to a maximu m of 40 participants on active 
agent, in order to better assess any effects of inhaled iloprost on secondary biomarkers. We expect up to 147 
people will participate in the “pre -screening” portion of this study.   
 
We expect 20% attrition during the study (for insufficient samples and non -compliance) , for a final evaluable 
sample of  32 active  QID.   
 
13.3 Accrual and Feasibility  
 
In a typical week, there are 5 -6 subjects identified who would qualify for chemop revention trials, and about 1/3 
of these subjects are agreeable to submit a screening sputum cytology sample and consider entering trials.  We 
plan to enroll a total of  up to 51 subjects  to allow  for attrition of 8-10 patients . We anticipate this taking about 
24-36 months to complete.  We also have subjects who participated in prior trials who have provided consent to 
be contacted for future studies.  
 
13.4 Primary Objective, Endpoint(s), Analysis Plan  
 
For primary objectives we will provide descriptive statistics (mean, SD, median, max, min and range) for 
toxicity  dropouts and compliance .  
 
In order to assess the  rates of toxicity , dropouts and compliance  we will use approximate 95% confidence 
intervals . With n=40, and 20% dropout rate, we get n=32, the approximate half -width of the 95% confidence 
interval  around the mean rate in a group is equal to or smaller than 2 x 0.5/sqrt( 32) = 0.18. This is compatible 
with the difference of 18% observed in Phase III study ( ref 35 ). Although we will not be able to study each 
toxicity per se, due to small number of subjects and their rare appearance, we will be able to assess a total 
number of toxicities per subject in tr eatment and placebo groups. Comparison between group B and B -control 
will follow the confidence interval approach outlined above for comparison of groups A and B. Group A will 
not be compared to B -control.  
 
13.5 Secondary Objectives, Endpoints, Analysis Plans  
 
For Secondary outcomes we will provide descriptive statistics  for a) Effect on endobronchial histology,  with the 
primary parameter being worst histology at matched sites; additional outcomes will be average histology, 
dysplasia index and response, as described15) b) Ef fect on expectorated sputum cytology, both by standard 
analysis and by an automated three dimensional technique  (Detecting dysplasia by LuCED is a research effort. 
The endpoint assessment will be limited to a binary indication of dysplasia by LuCED compare d to cases with 
confirmed dysplasia by histology)  c) Effect on serum proteins as  quantitated by aptamer based analysis, d) 
Effect on endobronchial brushing gene expression, focusing on prostacyclin -targeted pathways, and e) 
improvement in COPD as measured by ABG (improved ventilation perfusion matching), pulmonary function 
testing, 6 minute walk distance, and quality of life (St. George’s respiratory questionnaire, COPD assessment 
test [CAT]). Project statistician Dr. Jovanovic will supervise all of the ana lyses of primary and secondary 
outcomes.   
 
NWU2013 -02-01 
Version 3.9, April  19, 201 9 
 
 –37– When measuring global gene expression a concern is multiple testing and the generation of false positives, given 
the thousands of statistical tests needed to survey the entire genome.  We will control for multiple  testing by 
applying a strict false discover rate (FDR) of less than 1% to all gene lists used to define inhaled iloprost 
exposure.  Iloprost -specific profiles will be further refined through bioinformatics analysis.  Ingenuity pathway 
analysis (IPA) (www. ingenuity.com) will be used to identify over -represented pathways and networks contained 
within the affected genes using a Fisher’s Exact Test p -value of less than 0.01.  We will also use IPA to identify 
master regulators associated with our expression pro files, based on the over -representation of their target genes.  
 
Our ultimate goal is to identify biomarkers that will indicate a positive reactivity to iloprost from an 
endobronchial sample.   The ideal biomarkers for this purpose would be ones that are ea sy to interpret and have 
a biological basis for their use.  To these ends, we will use strict statistical criteria, correcting for multiple 
testing, to select our genes of interest.  Our selected biomarkers will also demonstrate a strong biological 
connect ivity to other genes affected by iloprost exposure, as evidence of being associated in the top significant 
pathways and networks as assessed by IPA.  Any proposed transcriptional biomarker will be validated in an 
additional cohort using RT -PCR.  The transc ribed proteins for any promising transcriptional markers will also 
be explored as potential signatures for iloprost exposure, based on the ease and relative quickness of this method 
of detection for clinical purposes.    
 
13.6 Reporting  and Exclusions  
 
Com pliance is an outcome directly measured as the fraction of prescribed inhalations actually administered.  In 
previous similar chemoprevention studies we have conducted, dropout  rate has been approximately 15% (similar 
in both placebo and active drug arms).   Non-compliance will not result in removal from study.  The primary 
analysis of secondary endpoints will be on an intention to treat basis.  Further secondary statistical analyses may 
be conducted based on varying degrees of compliance.  
 
13.7 Evaluation o f Toxicity  
 
All participants will be evaluable for toxicity from the time they take study drug through the day 90 study visit  
(study visit 4 on our calendar and corresponds to a one month visit after completing the 60 day treatment 
period) , even if they have been taken off study  for any reason . 
 
13.8 Evaluation of Response  
 
All participants included in the study will be assessed for response to intervention, even if there are major 
protocol deviations or if they are ineligible. All of the participants who  met the eligibility criteria (with the 
possible exception of those who did not receive study agent) will be included in the main analysis. All 
conclusions regarding efficacy will be based on all eligible participants.  
Sub-analyses may be performed on the subsets of participants, excluding those for whom major protocol 
deviations have been identified (e.g., early death due to other reasons, early discontinuation of intervention, 
major protocol violations, etc.). However, sub -analyses may not serve as the ba sis for drawing conclusions 
concerning efficacy, and the reasons for excluding participants from the analysis should be clearly reported. For 
all measurements of response, the 95% confidence intervals should be provided.  
 
13.9 Interim Analysis  
 
N/A 
 
13.10  Ancillary Studies  
 
N/A 
 
NWU2013 -02-01 
Version 3.9, April  19, 201 9 
 
 –38– 14. ETHICAL AND REGU LATORY CONSIDERATION S 
 
14.1 Form FDA 1572  
 
Prior to initiating this study, the Protocol Lead Investigator at the Lead or Participating Organization(s)  will 
provide a signed Form FDA 1572 stating that the study wi ll be conducted in compliance with regulations for 
clinical investigations and listing the investigators, at each site that will participate in the protocol. All personnel 
directly involved in the performance of procedures required by the protocol and the collection of data should be 
listed on Form FDA 1572.  
 
14.2 Other Required Documents  
 
14.2.1  Signed and dated current (within two years) CV or biosketch for all study personnel listed on the Form 
FDA 1572 and Delegation of Tasks form for the Lead Organizat ion and all Participating Organizations. CVs or 
biosketches do not need to be updated for participating study staff after drug shipment authorization (DSA).  
 
14.2.2  Current medical licenses (where applicable) for all study personnel listed on Form FDA 1572  and 
Delegation of Tasks form for the Lead Organization and all Participating Organizations.  
 
14.2.3  Lab certification ( e.g., CLIA, CAP) and lab normal ranges for all labs listed on Form FDA 1572 for the 
Lead Organization and all Participating Organizations.  
 
14.2.4  Documentation of Good Clinical Practice training for all study personnel listed on the FDA Form 1572 
and Delegation of Tasks form for the Lead Organization and all Participating Organizations.  
 
14.2.5  Documentation of Federalwide Assurance (FWA) number for the Lead Organization and all 
Participating Organizations.  
 
14.2.6  Signed Investigator’s Brochure/Package Insert acknowledgement form  
 
14.2.7  Delegation of Tasks form for the Lead Organization and all Participating Organizations si gned by the 
Principal Investigator for each site and initialed by all study personnel listed on the form  
 
14.2.8  Signed and dated NCI, DCP Financial Disclosure Form for all study personnel listed on Form FDA 
1572 for the Lead Organization and all Participating Or ganizations  
 
14.3 Institutional Review Board Approval  
 
Prior to initiating the study and receiving agent, the Investigators at the Lead Organization and the Participating 
Organization(s) must obtain written approval to conduct the study from the appropriat e IRB. Should changes to 
the study become necessary, protocol amendments will be submitted to the DCP PIO according to DCP 
Amendment Guidelines. The DCP -approved amended protocol must be approved by the IRB prior to 
implementation  
 
14.4 Informed Consent  
 
All potential study participants will be given a copy of the IRB -approved Informed Consent to review. The 
investigator will explain all aspects of the study in lay language and answer all questions regarding the study. If 
the participant decides to particip ate in the study, he/she will be asked to sign and date the Informed Consent 
document. The study agent(s) will not be released to a participant who has not signed the Informed Consent 
document. Subjects who refuse to participate or who withdraw from the st udy will be treated without prejudice.  
 
NWU2013 -02-01 
Version 3.9, April  19, 201 9 
 
 –39– Participants must be provided the option to allow the use of blood samples, other body fluids, and tissues 
obtained during testing, operative procedures, or other standard medical practices for further research purpo ses. 
If applicable, statement of this option may be included within the informed consent document or may be 
provided as an addendum to the consent. A Model Consent Form for Use of Tissue for Research is available 
through a link in the DCP website.  
 
Prior t o study initiation, the informed consent document must be reviewed and approved by NCI, DCP, the 
Consortium Lead Organization, and the IRB at each Organization at which the protocol will be implemented. 
Any subsequent changes to the informed consent must b e approved by NCI, DCP, the Consortium Lead 
Organization’s IRB, and then submitted to each organization’s IRB for approval prior to initiation.  
 
14.5 Submission of Regulatory Documents  
 
All regulatory documents are collected by the Consortia Lead Organization and reviewed for completeness and 
accuracy. Once the Consortia Lead Organization has received complete and accurate documents from a 
participating organization, the Consortium Lead Organization will forward the regulatory documents to the DCP 
Regulatory Contractor:  
 
 Paper Document/CD -ROM Submissions : 
 Regulatory Affairs Department  
 CCS Associates  
 2001 Gateway Place, Suite 350 West  
 San Jose, CA 95110  
 Phone: 650 -691-4400  
 Fax: 650 -691-4410  
 
 E-mail Submissions : regulatory@ccsainc.com  
 
Regulatory documents that do not require an original signature may be sent electronically to the Consortium 
Lead Organization for review, which will then be electronically forwarded to the DCP Regulatory Contractor.  
 
14.6 Other  
 
This trial will be conducted in compliance with the protocol, Good Clinical Practice (GCP), and the applicable 
regulatory requirements.  
 
14.6.1 Non-physical risks of genetic research  
 
Anxiety and stress may arise as a result of the anticipation that unwanted information regarding disease 
related DNA and RNA sequencing or disease tendencies. Patients will be clearly informed that the data 
related to DNA sequencing and genetic analysis is  coded, investigational and will not be shared with 
patients, family members or health care providers.  
 
This includes the risk that data related to genotype, DNA sequencing or risk for disease tendency or trait 
can be released to members of the public, in surers, employers, or law enforcement agencies. Although there 
are no plans to release results to the patients, family members or health care providers, this risk will be 
included in the informed consent document.  
 
15. FINANCING, EXPEN SES, AND/OR INSURANC E 
 
All research related costs associated with participating in this study will be paid for, and will not be the 
responsibility of the participant  
NWU2013 -02-01 
Version 3.9, April  19, 201 9 
 
 –40–  
NWU2013 -02-01 
Version 3.9, April  19, 201 9 
 
 –41– REFERENCES  
 
 (1)  Tong L, Spitz MR, Fueger JJ, Amos CA. Lung carcinoma in former smokers. Cancer 1996;78:1004 -10. 
 (2)  Keith RL, Miller YE. Lung cancer chemoprevention: current status and future prospects. Nat Rev Clin Oncol 
2013;10:334 -43. 
 (3)  Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10 -29. 
 (4)  Nicholson AG, Perry L J, Cury PM, Jackson P, McCormick CM, Corrin B, et al. Reproducibility of the 
WHO/IASLC grading system for pre -invasive squamous lesions of the bronchus: a study of inter -observer and 
intra-observer variation. Histopathology 2001;38:202 -8. 
 (5)  Jonsson S, Varella -Garcia M, Miller YE, Wolf HJ, Byers T, Braudrick S, et al. Chromosomal aneusomy in 
bronchial high -grade lesions is associated with invasive lung cancer. Am J Respir Crit Care Med 2008;177:342 -7. 
 (6)  Lam S, Kennedy T, Unger M, Miller YE, Gelmont D , Rusch V, et al. Localization of bronchial intraepithelial 
neoplastic lesions by fluorescence bronchoscopy. Chest 1998;113:696 -702. 
 (7)  Keith RL, Miller YE, Gemmill RM, Drabkin HA, Dempsey EC, Kennedy TC, et al. Angiogenic squamous 
dysplasia in bronchi of individuals at high risk for lung cancer. Clin Cancer Res 2000;6:1616 -25. 
 (8)  Kisley LR, Barrett BS, Dwyer -Nield LD, Bauer AK, Thompson DC, Malkinson AM. Celecoxib reduces 
pulmonary inflammation but not lung tumorigenesis in mice. Carcinogenesis 2002; 23:1653 -60. 
 (9)  Duperron C, Castonguay A. Chemopreventive efficacies of aspirin and sulindac against lung tumorigenesis in A/J 
mice. Carcinogenesis 1997;18:1001 -6. 
 (10)  Cuzick J, Otto F, Baron JA, Brown PH, Burn J, Greenwald P, et al. Aspirin and non-steroidal anti -inflammatory 
drugs for cancer prevention: an international consensus statement. Lancet Oncol 2009;10:501 -7. 
(11)  Rothwell PM, Fowkes FG, Belch JF, Ogawa H, et al. Effect of daily aspirin on long -term risk of death due to 
cancer: analysi s of individual patient data from randomised trials. Lancet, 2011; 377(9759):31 -41. 
 (12)  Keith RL, Miller YE, Hoshikawa Y, Moore MD, Gesell TL, Gao B, et al. Manipulation of pulmonary prostacyclin 
synthase expression prevents murine lung cancer. Cancer Res 2002;62:734 -40. 
 (13)  Keith RL, Miller YE, Hudish TM, Girod CE, Sotto -Santiago S, Franklin WA, et al. Pulmonary prostacyclin 
synthase overexpression chemoprevents tobacco smoke lung carcinogenesis in mice. Cancer Res 2004;64:5897 -
904. 
 (14)  Nemenoff R, Meyer AM, Hudish TM, Mozer AB, Snee A, Narumiya S, et al. Prostacyclin prevents murine lung 
cancer independent of the membrane receptor by activation of peroxisomal proliferator --activated receptor gamma. 
Cancer Prev Res (Phila Pa) 2008;1:349 -56. 
 (15)  Keith RL, Blatchford PJ, Kittelson J, Minna JD, Kelly K, Massion PP, et al. Oral iloprost improves endobronchial 
dysplasia in former smokers. Cancer Prev Res (Phila) 2011;4:793 -802. 
(16)  Prindiville SA, Beyers T, Hirsch FR, Franklin WA, et al. Sputum cyt ological atypia as a predictor of incident lung 
cancer in a cohort of heavy smokers with airflow obstruction. Cancer epidemiology, biomarkers & prevention 
2003; 12(10):987 -93. 
(17)  Schirner M, Schneider MR. Inhibition of metastasis by cicaprost in rats wi th established SMT2A mammary 
carcinoma growth. Cancer Detect Prev 1997;21:44 -50. 
(18)  Schneider MR, Schirner M, Lichtner RB, Graf H. Antimetastatic action of the prostacyclin analogue cicaprost in 
experimental mammary tumors. Breast Cancer Res Treat 1996; 38:133 -41. 
NWU2013 -02-01 
Version 3.9, April  19, 201 9 
 
 –42– (19)  Olschewski H, Hoeper MM, Behr, J, Ewert R, Meyer A, et al. Long -term therapy with inhaled iloprost in patients 
with pulmonary hypertension.  Respiratory Medicine 2010; 104.5: 731 -40. 
    (20) Wilbur, D. C., et al. "Automated 3 -dimensional morphologic analysis of sputum specimens for lung cancer 
 detection: Performance characteristics support use in lung cancer screening." Cancer Cytopathol.  123.9 (2015): 
 548-56. 
 
    (21)  Mascaux C, Feser WJ, Lewis MT, Baron AE, Coldren CD, Merrick DT, et  al. Endobronchial miRNAs as 
biomarkers in lung cancer chemoprevention. Cancer Prev Res (Phila) 2012.  
 (22)  Ostroff RM, Bigbee WL, Franklin W, Gold L, Mehan M, Miller YE, et al. Unlocking biomarker discovery: large 
scale application of aptamer proteomic t echnology for early detection of lung cancer. PLoS One 2010;5:e15003.  
 (23)  Tockman MS, Mulshine JL, Piantadosi S, Erozan YS, Gupta PK, Ruckdeschel JC, et al. Prospective detection of 
preclinical lung cancer: results from two studies of heterogeneous nucl ear ribonucleoprotein A2/B1 
overexpression. Clin Cancer Res 1997;3:2237 -46. 
 (24)  Peebles KA, Dwyer -Nield LD, Malkinson AM. Altered expression of splicing factor, heterogeneous nuclear 
ribonucleoprotein A2/B1, in mouse lung neoplasia. Mol Carcinog 2007;46 :887-900. 
 (25)  Tauler J, Zudaire E, Liu H, Shih J, Mulshine JL. hnRNP A2/B1 modulates epithelial -mesenchymal transition in 
lung cancer cell lines. Cancer Res 2010;70:7137 -47. 
 (26)  Sun Y, Lodish HF. Adiponectin deficiency promotes tumor growth in mice b y reducing macrophage infiltration. 
PLoS One 2010;5:e11987.  
 (27)  Astapova O, Leff T. Adiponectin and PPARgamma: cooperative and interdependent actions of two key regulators 
of metabolism. Vitam Horm 2012;90:143 -62. 
 (28)  Gustafson AM, Soldi R, Anderlind  C, Scholand MB, Qian J, Zhang X, et al. Airway PI3K pathway activation is an 
early and reversible event in lung cancer development. Sci Transl Med 2010;2:26ra25.  
 (29)  Spira A, Beane JE, Shah V, Steiling K, Liu G, Schembri F, et al. Airway epithelial gen e expression in the 
diagnostic evaluation of smokers with suspect lung cancer. Nat Med 2007;13:361 -6. 
(30)  Black CM, Halkier -Sorensen L, Belch JJ, Ullman S, et al. Oral iloprost in Raynaud’s phenomenon secondary to 
systemic sclerosis: a multicentre, placebo -controlled, dose -comparison study. British journal of rheumatology 
1998; 37(9):952 -60. 
(31)  Tockman MS, Anthonisen NR, Wright EC, Donithan MG. Airways obstruction and the risk for lung cancer. Ann 
Intern Med 1987;106:512 -8. 
 (32)  Sun YJ, Xiong CM , Shan GL, Gu Q, Zeng WJ, Lu XL, et al. Inhaled low -dose iloprost for pulmonary 
hypertension: a prospective, multicenter, open -label study. Clin Cardiol 2012;35:365 -70. 
NWU2013 -02-01 
Version 3.9, April  19, 201 9 
 
 –43– CONSENT FORM  
 
                          Department of Veterans Affairs                 Informed Consent Form  
Valid Through:                    R&D Stamp:  COMIRB Approval Stamp/Date:  
 
 
Protocol Version Date: 4/19/2019 (v3.9)  
Consent Version Date:  4/19/2019    
Subject Name: ______________________ ___________________________Date: _____________ ___ 
Title  of Study:  NWU2013 -02-01: A Phase I Trial of Inhaled Iloprost for the Prevention of Lung Cancer in Former 
Smokers  
Prin cipal Investigator:  York E. Miller , M.D.                                             VAMC :   554_________                  
            
VA Investigator: York E. Miller , M.D.                                                        COMIRB#__ 14-1247 _________  
 
 
You are being asked to be in a research study.  This form provides you with information about this study. A 
member of the research team will describe this study to you and answer all of your questions. Please read the 
information below and ask questions ab out anything you don’t understand before deciding whether or not to 
take part.  
 
Why is this study being done?  
This study is designed to learn more about the safety and effectiveness of an investigational drug called inhaled 
iloprost (Ventavis® ). The U.S. Food and Drug Administration (FDA) is the U.S. government agency that 
reviews the results of research and decides if a drug can be sold in the U.S. Inhaled iloprost is approved by the 
FDA for treating a disease of the lungs, called pulmonary hyperten sion.  However, Inhaled iloprost  may also be 
effective at preventing lung cancer in people at higher risk for developing lung cancer, such as yourself, a 
former smoker who has been found to have abnormal cells in your sputum  or airways . Because inhaled iloprost 
has not yet been demonstrated to be effective, nor approved for preventive treatment in lung cancer, it is 
considered investigational.      
When lung cells are looked at under a microscope and tested in the lab, they often show changes that tell us t hey 
can turn into cancer.  These signs or cell changes are called biomarkers.  We want to learn if inhaled iloprost can 
stop these cells from turning into cancer.  We also want to find out what side effects patients might have if they 
take inhaled iloprost  for 2 months . 
   
You are being asked to be in this research study because you are at risk to develop lung cancer. People who are 
at risk for lung cancer and choose not to participate in a study are usually followed closely by their doctor to 
watch for the  development of cancer. Your participation in this study is voluntary. If you decide not to 
participate in this research study, it will not affect the treatment that your doctors would normally give you.  If 
you decide not to take part in this study, you h ave other choices.  For example:  
 You may choose to have the usual approach described above.  
 You may choose to take part in a different study, if one is available.  
 Or you may choose to do nothing  
We plan to enroll up to 5 1 participants this treatment part of the study . 
 
 

NWU2013 -02-01 
Version 3.9, April  19, 201 9 
 
 –44– Inhaled iloprost  will be called “the study drug” for the rest of this consent form.  
 
How long will I be in this study?  
Your first screening visit will take about 6 hours for all the procedures to be completed.  If you are eligible for the 
study, you will be on the study drug for 2 months.  The study doctors will continue to watch you for side effects 
and follow your condit ion for 1 month after you have stopped the study drug.  You will be in the study for a total 
of about 3 ½ months.  
What happens if I join this study?  
If you join the study, you will be asked to do the following after you sign the consent form.  
Before the S tudy (Screening period)  
You will first go through several tests and procedures to make sure that you are eligible to take part in the study.  
The following list of exams, tests, and procedures except for the bronchoscopy are medical treatments that you 
will get because you are in this research study. The National Cancer Institute (NCI) will pay for those.   If your 
sputum shows  moderate or greater  changes to normal cells  the bronchoscopy would be a test that you would 
have to get for your condition even if you were not in this study.  Some of the blood, urine, and precancer tissue, 
as described below, will be taken for the study during screening.  These samples are required in order for you to 
take part in this study because the research on the samples is an  important part of the study for researchers to 
learn how to diagnose and treat lung cancer.  
 Physical exam (including your height, and weight)  
 Vital signs (including blood pressure, heart rate, and temperature)  
 Review of your medical history (including a review of any medications you are currently taking, and 
smoking history)  
 Performance status evaluation (what type of daily activities you can do)  
 Research Blood tests:  The total blood drawn will be 2½ ounces (approximately 5 tablespoons of blood). 
The bloo d tests performed will determine your eligibility, follow your safety, and stored for research  
 Research Pregnancy test for women who are able to become pregnant  
 Urine sample  
 Electrocardiogram (EKG) – a painless tra cing of your heart’s rhythm   
 Sputum Sample:  A sputum sample will be done at this visit only if you have not provided us with a 
sample within the last 3 months.  You will collect six  coughed sputum samples.  Each sample will 
consist of coughing up sputum (once a day for six days).  You will be instructed on how to collect and 
handle these samples.  If you are not able to cough up sputum you may have a sputum induction with 
hypertonic saline performed in the Denver VA PFT laboratory.  
 Bronchoscopy:   
o This is a test to view the lung airways to d iagnose lung disease.   
o A bronchoscope is a flexible device used to see the inside of the lungs.  
o You will get some medicine to help you relax and to dry your mouth, nose and airway.  Your 
nose, throat, vocal cords and windpipe will be sprayed with Lidocai ne (numbing medicine) to 
keep you from coughing and to numb your airways.   
o During the procedure a biopsy  in your airways will be obtained (from at least six areas, 
approximately 1 -2 mm in size each), and brushes will also be done to sample the cells that line 
the airways.  
NWU2013 -02-01 
Version 3.9, April  19, 201 9 
 
 –45– o The bronchial biopsy results will take one to three weeks to be reported.  In the highly unlikely 
event that a finding, such as invasive cancer or carcinoma in situ, with clinical importance is 
discovered you will be taken off of study an d you and your healthcare provider will be alerted 
to this.  
o Investigators may do genetic or genomic research studies on the tissue obtained in the biopsies 
taken during your bronchoscopy.  This tissue may be used for the analysis of your RNA and 
DNA.  RNA and DNA are the ‘instruction book’ your body uses in all the cells in your body. 
These  tests will help investigators to test whether your airway cells respond to iloprost in the 
laboratory.  
o You will not be able to drive yourself home after the test so you will need to make plans for a 
ride home.  
o You will receive a telephone call about 24 hours and 72 hours after your test to see how you are 
feeling.   
o You will receive instructions to call us  if you develop any of the following complications within 
30 days after the bronchoscopy:   
 fever  
 increased sputum  
 increased shortness of breath, and any feeling that your breathing condition has gotten 
worse  
 Pulmonary Function Test (PFT):  This breathing  test looks at how well your lungs work.  You will blow 
at a fast and long pace into a mouthpiece on a recording device (spirometer).  
 Carbon Monoxide Measurement:  You will breath e normally into a mouthpiece on a recording device 
(smokerlyzer) in order to test the levels (amount) of carbon monoxide in your body.   
 Six-Minute Walk Distance (6MWT):  A 6 -minute Walk Distance test is used to find out how much you 
are able to exercise.  The test will measure how far you can walk on a flat surface in 6 minutes.   
 Questionnaire:  You will be asked to complete 4 separate questionnaires which have questions about 
your lung/respiratory (breathing in/out) problems. You are free to skip any questions that you prefer not 
to answer.  
During the Study  
If the exams, tests, a nd procedures show that you can be in this study, and you choose to take part, then you will 
need the following research -related tests and procedures during the treatment period.  
Study Drug Treatment  
What are the study groups?  
 This study has just one group  – Iloprost  inhaled four times per day  
 
Participants  will be asked to take the study drug for 2 months . 
 
Visit 1  
You will meet with the study coordinator to receive the study drug  and learn how to use the nebulizer to take the 
study drug . 
 You will receive the study dru g by using a nebulizer. Th e nebulizer is a device used to reduce liquid 
forms of the drug into a fine spray that you breathe in (inhale).   The nebulizer is lightweight, small, and 
has an internal rechargeable battery like a cell phone.   
NWU2013 -02-01 
Version 3.9, April  19, 201 9 
 
 –46–  You will be trained on how to take the study drug , and how to use and clean the nebulizer. You will also 
view a video about using the nebulizer.  
 It is important to note that the study drug solution should not be allowed to come in contact with the 
eyes. You will be advised what to do in the event s ome solution comes in contact with you r eyes. 
 
 You will take first dose in the clinic in a private room under the supervision of the study coordinator 
and/or study physician.  
 
 You will be observed for 30 minutes after your first dose.  
 
 You will take the study drug  every 4 -6 hours.  
 Each treatment will take about 10-15 minutes.  
 You will be sent home with the study drug and nebulizer to use  daily as instructed, and with a drug 
diary to record taking each dose.  
Day 15  
You will receive a telephone call to review any medications you are currently taking and any side effects that 
you have had within the past 15 days.  
Visit 2 (Month 1 end)  
You wi ll be asked to bring in all unused study medication, the nebulizer, and the drug diary to your 
appointment.  
 
You will have the following tests/procedures:  
 Physical exam (including your height, and weight)  
 Vital signs (including blood pressure, heart rate,  and temperature)  
 Review of your medical history (including a review of any medications you are currently taking, and 
smoking history)  
 Performance status evaluation (what type of daily activities you can do)  
 A review of any side effects that you have had w ithin the past month  
 Blood draw. ½ ounce for routine blood tests (approximately 1 tablespoon)".  
 Research Carbon Monoxide Measurement  
Visit 3 (Month 2 end)  
You will have the following tests/procedures:  
 Physical exam (including your height, and weight)  
 Vital signs (including blood pressure, heart rate, and temperature)  
 Review of your medical history (including a re view of any medications you are  currently taking, and 
smoking history)  
 Performance status evaluation (what type of daily activities you can do)  
 A review of any side effects that you have had within the past month.  
 Research Blood draw. The total blood drawn will be 2 ½ ounces (approximately 5 tablespoons of 
blood) . 
NWU2013 -02-01 
Version 3.9, April  19, 201 9 
 
 –47–  Research Carbon Monoxide Measurement:   
 Urine sample  
 Sputum Sample  
 Research Bronchosc opy:   
 Pulmonary Function Test (PFT)  
 Six-Minute Walk Distance (6MWT)  
 Questionnaire  
Visit 4 (Month 3 end)  
You will have the following tests/procedures:  
 Physical exam (including your height, and weight)  
 Vital signs (including blood pressure, heart rate, and temperature)  
 Review of your medical history (including a review of any medications you are currently taking, and 
smoking history)  
 Performance status evaluation (what type of daily activities you can do)  
 A review of any side effects that you have had within  the past month.  
 Research Carbon Monoxide Measurement  
Further follow -up may be required if you experience side effects from study participation.  
What are the possible discomforts or risks?   
Any procedure has possible risks and discomforts. The procedures  in this study may cause all, some, or none of 
the risks or side effects listed below.  Rare, unknown, or unforeseeable (unexpected) risks also may occur.  
Discomforts you may experience while in this study include the following:  
Bronchial biopsy and brush ings: The bronchial biopsy and brushings  are very safe.  However, no test is 
entirely free of any risk.  The risks are as follows:  
Main Risks:  
 Bleeding from biopsy sites  
 Infection  
Uncommon Risks:  
 Arrhythmias (abnormal heart beat)  
 Breathing difficulties  
 Fever 
 Low blood oxygen  
 Abnormal collection of air in the lung which may cause difficulty in breathing  (Pneumothorax)  
 Sore throat  
 Chest pain  
 Heart attack  
Rare Risks when conscious sedation is used:  
NWU2013 -02-01 
Version 3.9, April  19, 201 9 
 
 –48–  Change in blood pressure  
 Slower heart rate  
 Nausea  
 Headache  
 Vomiting  
When a biopsy is taken, there is a risk of severe bleeding (hemorrhage).  There is a risk of choking if anything 
(including water) is swallowed before the numbing medicine wears off.  
Sometimes antibiotics and/or corticosteroids are needed if you a re showing signs of a lung infection.  It is not 
expected that patients will have all of these side effects. Other side effects may occur which were not seen 
before. Side effects are usually temporary and manageable.  
IV Infusion during bronchoscopy: Some pain can be expected when a needle is placed in your arm to infuse 
(give) fluids, in addition to minor discomfort of having the needle taped to your arm.  A bruise may form.  The 
risk of temporary clotting of the vein is about 1 person out of 100, and the risk of infection of a bruise or major 
blood loss occurs in less than 1 person out of 1,000. To lessen these discomforts, only trained doctors and 
technicians will be able to place the intravenous line.   
Other risks may include:  
Venipuncture (blood draw):  You will feel pain when the needle goes into the vein.  A bruise may form at the 
site.   A total of 5.5 ounces will be taken over the course of this study.  
Sputum samples: The risks of collecting sputum that you produce spontaneously are very small.  If y ou are 
given a solution to increase your coughed sputum there is a small  but significant risk of chest tightness , 
breathing difficulty , or severe respiratory distress .  If this happens, you will be given a breathing treatment, and 
you will be watched in th e office or clinic until you feel better , and if necessary, transferred to the Emergency 
Department .  Severe shortness of breath o r chest tightness is a very rare occurrence . 
Pulmonary Function Test (PFT): There is a small risk of fainting, dizziness, and lightheadedness.  
EKG: This is a test to check the electrical activity of your heart.  There are usually no risks.  Because this exam 
only checks electrical impulses and does not give electricity, there is no risk of shock. An EKG is done without 
going into the body or using dyes or x -rays, so there should be no pain or risk. You may feel discomfort similar 
to pulling a band aid when the electrodes placed on your chest are removed.  
Six-Minute Walk Test:  Changes in blood pressure, heart rate, and fainting can  happen, and in very rare cases, 
heart attack or stroke.  Trained staff and emergency equipment are available if any of these things happen.  
Side Effects of the Study Drug:  
 
COMMON, SOME MAY BE SERIOUS  
In 100 people receiving, more than 20 people may have:  
 Red face (flushing)  
 Increased cough  
 Headache  
 
NWU2013 -02-01 
Version 3.9, April  19, 201 9 
 
 –49– OCCASIONAL, SOME MAY BE SERIOUS  
In 100 people receiving, from 4 to 20 people may have:  
 Tightness of jaw muscles that makes it hard to open the mouth  
 Muscle cramps  
 Pain in the chest, back, tongue or mouth  
 Difficulty sleeping  
 Low blood pressure, which may cause symptoms of dizziness, lightheadedness, or feeling 
faint.  
 Increased low blood pressure effect when taking blood pressure lowering medications  
 Nausea  
 Vomiting  
 Abnormal lab tests related to th e liver  
 “Flu-like” symptoms such as fever, chills, body aches, muscle pain  
 Irregular heartbeat  
 Bleeding, including nose bleed, spitting up blood  
 Infection in the lungs  
 
POSSIBLE, SOME MAY BE SERIOUS  
The frequency of some individual side effects has not yet been determined:  
 Allergic reaction which may cause itching, rash, low blood pressure, wheezing, shortness of 
breath, swelling of the face or throat  
 Feeling short of breath or wheezing without allergic reaction. This is more common in people 
who have a  history of asthma.  
 Diarrhea  
 Nasal congestion  
 Changes in taste  
 Heart failure which may cause shortness of breath, swelling of ankles, and tiredness  
 Swelling in the hands or feet  
 Kidney failure  
 Abnormal blood test related to how well your blood clots (prevents bleeding)  
 Increased risk of bleeding, particularly in patients who are on blood thinners or medications 
to prevent blood clotting  
 Bleeding in the brain that can be life threatening  
 Potential for harm to fetus and to infants who are nursing  
 Poten tial for higher blood levels in patients with liver abnormalities.  
 
NWU2013 -02-01 
Version 3.9, April  19, 201 9 
 
 –50– You should not get pregnant, breastfeed, or father a baby while in this study.  If any of these occur, you should 
report it to the study staff as soon as possible. Iloprost  could be very  damaging to an unborn baby.  Check with 
the study doctor about what types of birth control, or pregnancy prevention, to use while in this study.  If you 
become pregnant, the particular treatment or procedures involved in the study may involve risks to the  embryo 
or fetus which are currently unclear.  
Risks associated with information gained from genetic/ genomic testing:  Any genetic or genomic testing that 
will be done with your samples collected as part of this study are done for research purposes only.  T hese tests 
will be done at an unknown time in the future and we do not plan to contact you about the results of these tests. 
There is a very small possibility that we can discover something medically relevant that you should be told 
about.  In this case,  the princ ipal investigator will make every attempt to contact you and refer you to a certified 
genetic health professional if you desire .  Any cost associated with follow -up related to this medically relevant 
information will be your responsibility. It is v ery important to remember that any results we mi ght find do  
not substitute for clinical care at any point in time.  You may also experience anxiety or stress if we find 
anything medically relevant from genetic or genomic testing that you should be told abou t and that this 
information could be shared with others.  Any data related to genetic or genomic testing is coded, used for 
research only, and will not be shared with family members, health care providers, or insurance companies.  
The study may include risks that are unknown or unforeseeable or unexpected at this time . 
Risks of the usual care you receive (procedures done as standard of care) are not risks of the research and are not 
included in this consent form. You should talk with your health care pro viders if you have any questions about 
the risks of usual care.  
What are the possible benefits of the study?  
This study is designed to learn more about Lung Cancer. This study is not designed to treat any illness or to 
improve your health.  
Who is paying f or this study?  
This research is being paid for by funding through the National Cancer Institute (N CI). 
Will I receive money for participation on the study?   
You will be paid up to $250.00 at your completion of the trial, at your Visit 4. This money will help to cover any 
costs associated with participating on this study, such as travel, food, and time away from work.  If you 
withdraw from the study before Visit 4, the payment will be less, based on the number of study visits that you 
completed.  
The follow ing payments will be paid for each visit:  
Screening Visit 1 (includes bronchoscopy): $100  
Visit 1: $25  
Visit 2: $25  
Visit 3 (includes bronchoscopy): $100  
Total for four visits: $250  
 
It is important to know that payment for participation in a study is taxa ble income.  
 
Will I have to pay for anything?   
There will be no cost to you for participation in this study.  However, some veterans are required to pay co -
payments for medical care and services provided by the VA.  These co -payment requirements will cont inue to 
apply to medical care and services provided by the VA that are not part of this study but are standard of care 
(usual care you receive at the VA).  If you decide to participate in this study, you cannot be charged nor your 
insurance billed, for res earch -related interventions or procedures that are required by the study protocol.   
NWU2013 -02-01 
Version 3.9, April  19, 201 9 
 
 –51– Do I have to take part in this study?  
Taking part in this study is voluntary.  You have the right to choose not to take part in this study.  If you choose 
to take part, y ou have the right to stop at any time.  If you refuse or decide to withdraw later, you will not lose 
any benefits or rights to which you are entitled.  
If you do not take part or leave this study, you will still receive your normal medical care.  If you le ave this study, 
the only medical care that you will lose is the medical care you are getting as part of this study.  You might be able 
to get the same kind of medical care outside of the study.  Ask your study doctor about your options. If you want to 
withdraw from the study, you should contact the investigator to discuss what follow -up care could be most helpful 
to you.  
If there are any new findings during the study that may affect whether you want to continue to take part in it, 
you will be told about th em. 
Can I be taken out of the study?  
The study doctor may decide to stop your participation without your permission, if he or she thinks that being in 
the study may cause you harm, or for any other reason.  Also, the sponsor may stop the study at any time.  
What happens if I am injured or hurt during the study?    
Every reasonable safety measure will be used to protect your well -being. The Eastern Colorado Health Care 
System will provide necessary medical care and treatment for any injury that is a result of participation in this 
study for veterans and non-veterans .    Compensation for such an injury may be permitted by applicable federal 
laws and/or regulations.  The VA is not required to provide treatment for injuries in research studies if the 
injuries are caused by your non -compliance with study procedures.  
 
You should inform your care provider(s) if you decide to participate in this research study.  If you have 
questions about an injury related to the research, call Dr. York Miller  at 303 -393-2869 . 
 
Who do  I call if I have questions?  
The researcher carrying out this study at the VA is Dr. York Miller. You may ask any questions you have now.  
If you have any questions later you may call Dr. York Miller  at 303 -393-2869 .  You will be given a copy of this 
form to keep.  
If you have questions regarding your rights as a research subject, concerns or complaints about this research 
study, please call the Colorado Multiple Institutional Review Board (COMIRB) office at 303 -724-1055.  This is 
the Board that is responsible for ov erseeing the safety of human participants in this study.  If you want to verify 
that this study is approved, please contact the VA Research Office at 303.399.8020, ext. 2755.  Information can 
also be found at http://www.clinicaltrials.gov .  
Who will see my research information?  
Taking part in this study will involve collecting private information about you.  We will keep all research 
records that contain your identifiable health information confidential to the extent allowed by law.   Paper 
records about you will be kept in locked filing cabinets.  We will also keep an electronic copy of your study 
records on a secure server accessible only from a password protected computer database.  
We will try to keep your med ical records confidential, but it cannot be guaranteed.  Records that identify you 
(including your medical records and the consent form signed by you), may be looked at or portions of your 
records copied that identify you by others. These include:  
 Federal agencies such as the Food and Drug Administration (FDA), the  General Accountability Office 
(GAO), the Office of the Inspector General, Office for Human Research Protections (OHRP), and the 
Office of Research Oversight (ORO) that protect research subjects l ike you, may also copy portions of 
records about you.  
NWU2013 -02-01 
Version 3.9, April  19, 201 9 
 
 –52–  People at the Colorado Multiple Institution Review Board  
 The investigator and research team for this study  
 The sponsor ( National Cancer Institute ), study monitors or agents for the sponsor  
 Officials a t the institution where the research is being conducted, and officials at other institutions 
involved in this study who are in charge of making sure that we follow all of the rules for research  
 Our local VA Research and Development Committee  
 Colorado Statu e tumor Registry and Vital Statistics (for the purpose of learning whether or not you 
develop lung cancer).  
 UCD enver and its  Integrated Clinical Trials Management System  
 Northwestern University  
 The National Cancer Institute will obtain information from thi s clinical trial under data collection 
authority Title 42 U.S.C. 285.  
 VisionGate, Inc.  (a biotechnology company developing a test to distinguish cancer cells from  non 
cancer cells using  sputum samples)  
Information about you will be combined with informatio n from other people taking part in the study. We might 
talk about this research study at meetings.   We might also print the results of this research study in relevant 
journals.   But we will always keep the names of the research subjects, like you, private.   
Where can I get more information?  
 
You may visit the NCI website at http://cancer.gov/  for more information about studies or general 
information about cancer. You may also call the NCI Cancer Information Service to get the same 
information at: 1 -800-4-CANCER (1 -800-422-6237).  
 
We will ask you to sign a different form that talks about who can see your research records.   That form is called 
a HIPAA Authorization form.   It will mention  companies and universities who will see your research records.   
You have the right to request access to your personal health information from the Investigator.  To ensure proper 
evaluation of test results, your access to these study results may not be allowed until after the study has been 
completed.  
The HIPAA Authorization form that you will also be asked to sign will state when or if it expires. However, you 
may withdraw this authorization for use and disclosure of your personal health information by providing written 
request to the Investi gator. If you withdraw the HIPAA Authorization form, the Institution, the Investigator, the 
research staff, and the research Sponsor will no longer be able to use or disclose your personal health 
information from this study, except so far as that they have  already relied on this information to conduct the 
study.  
Is there other information I need to know?   
 Your samples collected under this protocol may be used for genetic or genomic studies and data from  
these studies w ill be deposited in the database of Genotypes and Phentoypes (dbGaP)  as a requirement 
of the National Cancer Inst itute.  Any information in the database  will be coded and will not contain any 
identifiable information about you, such as your name, phone, or address, but we still need  your 
permission to include your data in the database of Genotypes and Phentoypes . 
   Yes, I give my permission fo r study investigators to deposit de -identified data  from genetic  and gen omic  
studi es using my research samples in the database of Genotypes and Phentoypes          .  ____Initials  
NWU2013 -02-01 
Version 3.9, April  19, 201 9 
 
 –53–    
   No, you may not deposit  de-ident ified data  from genetic and genomic studies using my research samples in 
the database of Genotypes and Phentoypes  .                                                                           __Initials                                                            
 
 Re-contact.  We may  wish  to re-contact you in the future for additional studies you may be eligible to 
participate in.  These studies may be within the VA or outside the VA.  I give my permission for my 
study doctor (or someone he or she chooses) to contact me in the future t o ask me to take part in more 
research.   
  
   Yes, I am interested in being contacted to participate in future studies.  ____Initials  
 
   No, I am not interested in being contacted to participate in future studies. __Initials  
 
Agreement to be in this study  
I have read this form or it has been read to me.  A member of the research team has explained the study to me 
and answered my questions.  I have been told about the risks or discomforts and possible benefits of the study.  I 
have been told of other choices of treatment available to me.  
I have been told that I do not have to take part in this study.  My  refusal to participate will involve no penalty or 
loss of rights to which I am entitled.  I may withdraw from this study at any time without penalty or loss of VA 
or other benefits to which I am entitled.  
The results of this study may be published, but my  records will not be revealed unless required by law.  
In case there are medical problems or questions, I have been told I can call Dr. York  Miller at 303-393-2869 
during the day and at 303-393-2869 after hours.  If any medical problems occur in connection with this study, 
the VA will provide the necessary medical care.  
I choose to participate in this study.  A copy of this consent form will be placed in my medical record.   If I am 
not a veteran, a health record will be created for me in the VA computerized  patient record system (CPRS) to 
include my research records.  
 
Subject’s Signature: _____________________________    Date:________________  
Print name: ____________________________________  
 
Consent form explained by: _______________________     Date: _____ __________  
Print name: ____________________________________  
       
VA Additional Consent for Blood and Tissue for Research  
The study investigators  would like to keep some of the sputum, blood, urine, and tissue that is taken during the 
study but is not used for other tests. If you agree, the sputum, blood, urine, and tissue samples will be kept and 
may be used in future research to learn more about lung cancer. The research that is done with your sputum, 
blood, urine, and tissue samples is not designed to specifically help you. It might help people who have lung 
cancer and other diseases in the future. Reports about research done with your samples wi ll not be given to you 
or your doctor. These reports will not be put in your health records. The research using your sputum, blood, 
NWU2013 -02-01 
Version 3.9, April  19, 201 9 
 
 –54– urine, and tissue samples will not affect your care.  
The choice to let the study investigators keep the sputum, blood, urine , and tissue samples for future research is 
up to you. The specimens will be kept at the SPORE (Specialized Program of Research Excellence) Tissue Bank 
at the University of Colorado , Denver and accessed by study investigators.  Your samples will be labeled  with a 
code that doesn’t identify you directly (or list the specific minimal identifiers needed).  No matter what you 
decide to do, it will not affect the care that you will receive as part of the study. If you decide now that your 
sputum, blood, urine, a nd tissue samples can be kept for research, you can change your mind at any time and 
contact your study doctor to let him or her know that you do not want Dr. York Miller  to use your sputum, 
blood, urine, and tissue samples any longer, and they will no lon ger be used for research. Otherwise, they may 
be kept until they are used up, or until Dr. York Miller  decides to destroy them.  
In the future, people who do research with your sputum, blood, urine, and tissue samples may need to know 
more about your healt h. While the study investigators  may give those reports about your health, they will not 
give them your name, address, phone number or any other information that will let the research know who you 
are.  
Sometimes sputum, blood, urine, and tissue samples ar e used for genetic research (about diseases that are passed 
on in families). Even if your sputum, blood, urine, and tissue samples are used for this kind of research, the 
results will not be told to you and will not be put in your health records. Your sput um, blood, urine, and tissue 
samples will only be used for research and will not be sold. The research done with your samples may help to 
develop new products in the future, but there is no plan for you to be paid.  
A new Federal law, called the Genetic Inf ormation Nondiscrimination Act (GINA), generally makes it illegal 
for health insurance companies, group health plans, and most employers to discriminate against you, based on 
your genetic information. This law generally will protect you in the following wa ys:  
 Health insurance companies and group health plans may not request your genetic information that we 
get from this research.  
 Health insurance companies and group health plans may not use your genetic information obtained from 
this research when making d ecisions  regarding your eligibility or premiums.  
 Employers with 15 or more employees may not use your genetic information that we get from this 
research when making a decision to hire, promote, or fire you or when setting the terms of your 
employment.  
Be aware that this new Federal law does not protect you against genetic discrimination by companies that sell 
life insurance, disability insurance, or long -term care insurance.  
The possible benefits of research from your sputum, blood, urine, and tissue inclu de learning more about what 
causes lung cancer  and other diseases, how to prevent them and how to treat them. The greatest risk to you is the 
release of information from your health records.  Dr. York Miller  will protect your records so that your name, 
address and phone number will be kept private. The chance that this information will be given to someone else 
is very small. There will be no cost to you for any sputum, blood, urine, and tissue collected and stored by Dr. 
York Miller . 
Please read each senten ce below and think about your choice. After reading each sentence, circle “yes” or “no.” 
If you have questions, please talk to your doctor or nurse. Remember, no matter what you decide to do about the 
storage and future use of your sputum, blood, urine, an d tissue samples, you may still take part in the study.  
I give my permission for my sputum, blood, urine, and tissue to be stored in a central tissue bank at the SPORE 
Tissue Bank for future use by the study investigators:  
1. I give my permissions for my sput um, blood, urine, and tissue samples to be kept by Dr. York Miller  for 
use in future research to learn more about how to prevent, detect, or treat Lung Cancer.  
   Yes     No  _________Initials  
2. I give my permissions for my sputum, blood, urine, and tissue samples to be used for research about 
NWU2013 -02-01 
Version 3.9, April  19, 201 9 
 
 –55– other health problems (for example: causes of heart disease, o steoporosis, and diabetes).  
   Yes     No  _________Initials  
I agree to take part in the study having to do with research on sputum, blood, urine, and tissue as indicated 
above.  
 
Signature________________________________    Date____ _______  
Print Name:          
 
Consent form explained by:       Date:     
Print Name:          
 
Witness Signature:__________________________Date_________  
Print Name:          
 
Witness of Signature    
Witness of consent process   
 
NWU2013 -02-01 
Version 3.9, April  19, 201 9 
 
 –56– APPENDIX A  
 
Performance Status Criteria  
 
 
ECOG Performance Status Scale  
  
Karnofsky Performance Scale  
Grade  Descriptions  Percent  Description  
0 Normal activity. Fully active, able to 
carry on all pre -disease performance 
without restriction.  100 Normal, no complaints, no evidence of 
disease.  
90 Able to carry on normal activity; minor 
signs or symptoms of disease.  
1 Symptoms, but ambulatory. Restricted in 
physically strenuous activity, but 
ambulatory and able to carry out work of 
a light or sedentary nature ( e.g., light 
housework, office work).  80 Normal activity with effort; some signs 
or symptoms of disease.  
70 Cares for self, unable to carry on 
normal activity or to do active work.  
2 In bed <50% of the time. Ambulatory and 
capable of all self -care, but unable to 
carry out any  work activities. Up and 
about more than 50% of waking hours.  60 Requires occasional assistance, but is 
able to care for most of his/her needs.  
50 Requires considerable assistance and 
frequent medical care.  
3 In bed >50% of the time. Capable of only 
limited self -care, confined to bed or chair 
more than 50% of waking hours.  40 Disabled, requires special care and 
assistance.  
30 Severely disabled, hospitalization 
indicated. Death not imminent.  
4 100% bedridden. Completely disabled. 
Cannot carry on any self -care. Totally 
confined to bed or chair.  20 Very sick, hospitalization indicated. 
Death not imminent.  
10 Moribund, fatal processes progressing 
rapidly.  
5 Dead.  0 Dead.  
 
 
 
NWU2013 -02-01 
Version 3.9, April  19, 201 9 
 
 –57– APPENDIX B  
 
Patient Diary  
 
Participant Name_______________  
Participant ID__________________  
Dose_________________________  
Frequency_____________________  
 
DAY ___  
 
DATE: ___/____/____  
TIME: _____________  
TIME: _____________  
TIME: _____________  
TIME: _____________  
 
Please list any new 
symptoms or reasons for 
missed doses: 
____________________  
____________________  
____________________  
____________________  
____________________  
____________________  
____________________  
____________________  DAY ___  
 
DATE: ___/____/____  
TIME: _____________  
TIME: _____________  
TIME: _____________  
TIME: _____________  
 
Please list any new 
symptoms or reasons for 
missed doses: 
____________________  
____________________  
____________________  
____________________  
____________________  
____________________  
____________________  
____________________  DAY ___  
 
DATE: ___/____/____  
TIME: _____________  
TIME: _____________  
TIME: _____________  
TIME: _____________  
 
Please list any new 
symptoms or reasons for 
missed doses: 
_________________ ___ 
____________________  
____________________  
____________________  
____________________  
____________________  
____________________  
____________________  DAY ___  
 
DATE: ___/____/____  
TIME: _____________  
TIME: _____________  
TIME: _____________  
TIME: _____________  
 
Please list any new 
symptoms or reasons for 
missed doses: 
____________________  
____________________  
____________________  
____________________  
___________________ _ 
____________________  
____________________  
____________________  DAY ___  
 
DATE: ___/____/____  
TIME: _____________  
TIME: _____________  
TIME: _____________  
TIME: _____________  
 
Please list any new 
symptoms or reasons for 
missed doses: 
____________________  
____________________  
____________________  
____________________  
____________________  
____________________  
____________________  
____________________  DAY ___  
 
DATE: ___/____/____  
TIME: _____________  
TIME: _____________  
TIME: _____________  
TIME: _____________  
 
Please list any new 
symptoms or reasons for 
missed doses: 
____________________  
____________________  
____________________  
____________________  
____________________  
____________________  
____________________  
____________________  DAY ___  
 
DATE: ___/____/____  
TIME: _____________  
TIME: _____________  
TIME: _____________  
TIME: _____________  
 
Please list any new 
symptoms or reasons for 
missed doses: 
____________________  
____________________  
____________________  
____________________  
____________________  
____________________  
____________________  
____________________  
DAY ___  
 
DATE: ___/____/____  
TIME: _____________  
TIME: _____________  
TIME: _____________  
TIME: _____________  
 
Please list any new 
symptoms or reasons for 
missed doses: 
____________________  
____________________  
____________________  
____________________  
____________________  
____________________  
____________________  
____________________  DAY ___  
 
DATE: ___/____/____  
TIME: _____________  
TIME: _____________  
TIME: _____________  
TIME: _____________  
 
Please list any new 
symptoms or reasons for 
missed doses: 
____________________  
____________________  
____________________  
____________________  
____________________  
____________________  
____________________  
____________________  DAY ___  
 
DATE: ___/____/____  
TIME: _____________  
TIME: _____________  
TIME: _____________  
TIME: _____________  
 
Please list any new 
symptoms or reasons for 
missed doses: 
____________________  
____________________  
____________________  
____________________  
____________________  
____________________  
____________________  
____________________  DAY ___  
 
DATE: ___/____/____  
TIME: _____________  
TIME: _____________  
TIME: _____________  
TIME: _____________  
 
Please list any new 
symptoms or reasons for 
missed doses: 
____________________  
____________________  
____________________  
____________________  
____________________  
____________________  
____________________  
____________________  DAY ___  
 
DATE: ___/____/____  
TIME: _____________  
TIME: _____________  
TIME: _____________  
TIME: _____________  
 
Please list any new 
symptoms or reasons for 
missed doses: 
____________________  
____________________  
____________________  
____________________  
____________________  
____________________  
____________________  
____________________  DAY ___  
 
DATE: ___/____/____  
TIME: _____________  
TIME: _____________  
TIME: _____________  
TIME: _____________  
 
Please list any new 
symptoms or reasons for 
missed doses: 
____________________  
____________________  
____________________  
____________________  
____________________  
____________ ________  
____________________  
____________________  DAY ___  
 
DATE: ___/____/____  
TIME: _____________  
TIME: _____________  
TIME: _____________  
TIME: _____________  
 
Please list any  new 
symptoms or reasons for 
missed doses: 
____________________  
____________________  
____________________  
____________________  
____________________  
____________________  
____________________  
____________________  
 
Participant Signature: ______________________________________________________     Date: ________________
NWU2013 -02-01 
Version 3.9, April  19, 201 9 
 
 58 APPENDIX C  
 
Six Minute Walk Test Recording Sheet  
SIX MINUTE WALK TEST 1 OF 2  
INSTITUTION   
______________________________  PARTICIPANT ID  
_______________ _______  VISIT DATE  
__ __ / __ __ / __ __ __ __  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  1 Minute: SpO2 (%)  ______  
1 Minute: Heart Rate (bpm)   ______  
1 Minute: Dyspnea   ______  
1 Minute: Rests   ______  
2 Minutes: SpO2 (%)   ______  
2 Minutes: Heart Rate (bpm)   ______  
2 Minutes: Dyspnea   ______  
2 Minutes: Rests   ______  
3 Minutes: SpO2 (%)   ______  
3 Minutes: Heart Rate (bpm)   ______  
3 Minutes: Dyspnea   ______  
3 Minutes: Rests   ______  
4 Minutes: SpO2 (%)   ______  
4 Minutes: Heart Rate (bpm)   ______  
4 Minutes: Dyspnea   ______  
4 Minutes: Rests   ______  
5 Minutes: SpO2 (%)   ______  
5 Minutes: Heart Rate (bpm)   ______  
5 Minutes: Dyspnea   ______  
5 Minutes: Rests   ______  
6 Minutes: SpO2 (%)   ______  
6 Minutes: Heart Rate (bpm)   ______  
6 Minutes: Dyspnea   ______  
6 Minutes: Rests   ______  Predicted Maximum Heart Rate 
(220 -age):  
  ______  
Bronchodilator: Time since last 
dose (HH:MM):   ______  
Supplemental Oxygen Used?  ______  
Gait Aid Used?   ______  
Rest: SpO2 (%)   ______  
Rest: Heart Rate (bpm)  
  ______  
Rest: Dyspnea   ______  
NWU2013 -02-01 
Version 3.9, April  19, 201 9 
 
 59 SIX MINUTE WALK TEST 2 OF 2  
INSTITUTION   
______________________________  PARTICIPANT ID  
______________________  VISIT DATE  
__ __ / __ __ / __ __ __ __  
 
 
 
Comments:      
     __________________________________  
__________________________________  
__________________________________  
     __________________________________  
 
 
 
 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Signature: _____________________________________________  Date: _______________   Recovery 1 Minute: SpO2 (%)  
  ______  
Recovery 1 Minute: Heart Rate 
(bpm)  
  ______  
Recovery 1 Minute: Dyspnea  
  ______  
Distance (miles):   ______  
Limiting factor to the test: SOB   ______  
Limiting factor to the test: Low 
SpO2?   ______  
Limiting factor to the test: Leg 
fatigue?   ______  
Limiting factor to the test: Other   ______  
Other: Specify   ______  
NWU2013 -02-01 
Version 3.9, April  19, 201 9 
 
 60 APPENDIX D   
 
 
 
  
Signature: _____________________________________________  Date: _______________  
 
 
NWU2013 -02-01 
Version 3.9, April  19, 201 9 
 
 61 APPENDIX E  
 
THE ST. GEORGE’S HOSPITAL RESPIRATORY QUESTIONNAIRE (SGRQ)  
 
 
 
 
This questionnaire is designed to help us learn much more about how your  
breathing is troubling you and how it affects your life. We are using it to find out  
which aspects of your illness cause you most problems, rather than what  the  
doctors and nurses think your problems are.  
 
Please read the instructions carefully and ask questions if you do not understand anything. Do  
not spend too long deciding on your answers.  
 
 
 
 
 
 
Before completing the rest of the questionnaire:  
 
Please checkmark one box to show how you describe 
your present health:  
 
  
 
Very good  
  
 
Good  
  
 
Fair 
  
 
Poor  
  
 
Very poor  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright reserved  
P.W. Jones,  PhD  FRCP  
Professor of Respiratory Medicine,  
St. George’s, University of London,  
Jenner Wing,  
Cranmer Terrace,  Tel.  +44 (0) 20 8725 5371  
London SW17 ORE, UK.  Fax  +44 (0) 20 8725 5955  
 
E-1
NWU2013 -02-01 
Version 3.9, April  19, 201 9 
 
 62 St. George’s Respiratory Questionnaire  
PART 1  
 
Questions about how much chest problem you have had over the past 4 weeks.  
 
Please checkmark ( ) one box for each questio n: 
 
 Most 
days  
a week  Several 
days  
a week  A few 
days  
a month  Only with 
chest 
infections  Not  
at  
all 
1. Over the past 4 weeks, I have coughed:       
 
2. Over the past 4 weeks, I have brought up  
phlegm (sputum):       
 
3. Over the past 4 weeks, I have had shortness  
of breath:       
 
4. Over the past 4 weeks, I have had attacks  
of wheezing:       
 
5. During the past 4 weeks, how many severe or very  
unpleasant attacks of chest problem have you had?  
Please checkmark ( ) one box only : 
 more than 3 attacks   
 3 attacks   
 2 attacks   
 1 attack   
 no attacks   
 
6. How long did the worst attack of chest problem last:  
(Go to question 7 if you had no severe attacks)  
Please checkmark ( ) one box only : 
 a week or more   
 3 days or more   
 1 or 2 days   
 Less than a day   
 
7. Over the past 4 weeks, in an average week, how many good days  
(with little chest problem) have you had:  
Please checkmark ( ) one box only : 
 No good days   
 1 or 2 good days   
 3 or 4 good days   
 Nearly every day was good   
 Every day was good   
 
8. If you have a wheeze, is it worse in the morning:  
Please checkmark ( ) one box only : 
 No  
 Yes  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
E-2
NWU2013 -02-01 
Version 3.9, April  19, 201 9 
 
 63 St. George’s Respiratory Questionnaire  
PART 2  
 
Section 1  
 
How would you describe your chest condition?  
Please checkmark ( ) one box only : 
 The most important problem I have   
 Causes me quite a lot of problems   
 Causes me a few problems   
 Causes me no problem   
 
If you have ever had paid employment.  
Please checkmark ( ) one box only : 
 My chest problem made me stop work altogether   
 My chest problem interferes with my work or made me change my work   
 My chest problem does not a ffect my work   
 
Section 2  
 
Questions about what activities usually make you feel breathless these days . 
 
For each item , please 
checkmark ( ) the box as it 
applies to you these days : 
 True False  
 Sitting or lying still    
 Getting washed or dressed    
 Walking around at home    
 Walking outside on the level    
 Climbing up a flight of stairs    
 Climbing hills    
 Playing sports or games    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
E-3
NWU2013 -02-01 
Version 3.9, April  19, 201 9 
 
 64 St. George’s Respiratory Questionnaire  
PART 2  
 
Section 3  
 
Some more questions about your cough and breathlessness these days . 
For each item , please 
checkmark ( ) the box as it 
applies to you these days : 
 True False  
 My cough hurts    
 My cough makes me tired    
 I am breathless when I talk    
 I am breathless when I bend over    
 My cough or breathing disturbs my sleep    
 I get exhausted easily    
 
Section 4  
 
Questions about other effects that your chest problem may have on you these days . 
 
For each item , please 
checkmark ( ) the box as it 
applies to you these days : 
 True False  
 My cough or breathing is embarrassing in public    
 My chest problem is a nuisance to my family, friends or neighbours    
 I get afraid or panic when I cannot get my breath    
 I feel that I am not in control of my chest problem    
 I do not expect my chest to get any better    
 I have become frail or an invalid because of my chest    
 Exercise is not safe for me    
 Everything seems too much of an effort    
 
Section 5  
 
Questions about your medication. If you are taking no medication go straight to Section 6.  
 
For each item , please 
checkmark ( ) the box as it 
applies to you these days : 
 True False  
 My medication does not help me very much    
 I get embarrassed using my medication in public    
 I have unpleasant side effect s from my medication    
 My medication interferes with my life a lot    
 
 
 
E-4
NWU2013 -02-01 
Version 3.9, April  19, 201 9 
 
 65 St. George’s Respiratory Questionnaire  
PART 2  
 
Section 6  
 
These are questions about how your activities might be affected by your breathing.  
 
For each item , please checkmark () 
the box as it applies to you because 
of your breathing : 
 True False  
 I take a long time to get washed or dressed    
 I cannot take a bath or shower, or I take a long time    
 I walk slower than other people, or I stop for rests    
 Jobs such as housework take a long time, or I have to stop for rests    
 If I walk up one flight of stairs, I have to go slowly or stop    
 If I hurry or walk fast, I have to stop or slow down    
 My breathing makes it difficult to do things such as climbing up hill s, carrying  
 things up stairs, light gardening such as weeding, dancing, playing bowls or golf    
 My breathing makes it difficult to do things such as carrying heavy loads,  
 digging the garden or shovelling snow, jogging or walking  
 at 8 kilometres per hour, playing tennis or swimming    
 My breathing makes it difficult to do things such as very heavy manual work,  
 running, cycling, swimming fast or playing competitive sports    
 
 
 
Section 7  
 
We would like to know how your chest problem usually  affects your daily life.  
 
For each item , please checkmark ( ) 
the box as it applies to you because 
of your chest problem : 
 True False  
 I cannot play sports or games    
 I cannot go out for entertainment or recreation    
 I cannot go out of the house to do the groceries     I cannot do housework    
 I cannot move far from my bed or chair    
 
 
  
 
 
 
 
 
 
E-5 
 
NWU2013 -02-01 
Version 3.9, April  19, 201 9 
 
 66 St. George’s Respiratory Questionnaire  
 
 
Here is a list of other activities that your chest problem may prevent you doing 
(you do not have to checkmark these, they are just to remind you of ways in which 
your breathlessness may affect you):  
 
Going for walks or walking the dog  
Doing things at home or in the garden  
Sexual intercourse  
Going out to church or place of entertainment  
Going out in bad weather or into smoky rooms  
Visiting family or friends or playing with children  
 
 
Please write in any other important activities that your chest problem may stop you 
doing:  
 ................................ ................................ ...................   
 ................................ ................................ ...................   
 ................................ ................................ ...................   
 ................................ ................................ ...................   
 
Now, would you checkmark the box (one only)  which you think best describes how 
your chest affects you:  
 
It does not stop me doing anything I would like to do   
It stops me doing one or two things I would like to do   
It stops me doing most of the things I would like to do   
It stops me doing everything I would like to do   
 
Thank you for filling in this questionnaire. Before you finish, would you check to see that 
you have answered all the questions.  
 
 
 
Signature: ___________________________________________  Date: _______________  
 
 
 
 
 
 
NWU2013 -02-01 
Version 3.9, April  19, 201 9 
 
 67  
E-6 
APPENDIX F  
 
NWU2013 -02-01 
Version 3.9, April  19, 201 9 
 
 68  
 
 
APPENDIX G  
 
LIFE BRONCHOSCOPY PATIENT COMMUNICATION LOG  
Source Document  
 
Patient Name:         Patient Phone #:     
 
Pre-Case Communication:  
Date of Consent:        
(The patient verbalized understanding of the consent  and a copy of the signed consent was provided to the 
patient.)  
 
__________________________________________________________________________________________  
__________________________________________________________________________________________  
__________________________________________________________________________________________  
__________________________________________________________________________________________  
__________________________________________________________________________ ________________  
__________________________________________________________________________________________  
 
 
Signature:        Date:        
 
 
Procedure Date:  
 
Date:        Time:       
Physician:       Notified:      
  
 
 
24-Hour Follow -up: 
Date:        
 
Comments:  
__________________________________________________________________________________________  
__________________________________________________________________________________________  
________________________________________________________________ __________________________  
 
 
Signature:        Date: _______________  
 
 
 
 
G-1
NWU2013 -02-01 
Version 3.9, April  19, 201 9 
 
 69 72-Hour Follow -up: 
Date:         
 
Comments:  
__________________________________________________________________________________________  
__________________________________________________________________________________________  
__________________________________________________________________________________________  
 
The patient was instructed to call within 30 days if febrile or with incr eased sputum production, increasing 
shortness of breath, or any perceived deterioration of respiratory condition:   
Yes:     No:     
  
 
Signature:        Date: _______________  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
G-2 